data_1alg_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1alg _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.4 tp . . . . . 0 N--CA 1.492 1.647 0 N-CA-C 108.9 -0.778 . . . . 1.27 108.9 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 45.3 mm-40 -65.01 -31.74 73.12 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 109.234 -0.654 . . . . 0.71999999999999997 109.234 179.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -31.88 79.94 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.476 -1.45 . . . . 0.45000000000000001 109.476 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -80.18 -37.95 32.26 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.552 -0.969 . . . . 0.56000000000000005 108.401 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.86 -42.71 99.86 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 109.287 -0.634 . . . . 0.66000000000000003 109.287 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.5 p -74.32 -37.13 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.686 . . . . 1.1499999999999999 109.662 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.69 -51.14 61.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.523 -0.736 . . . . 0.54000000000000004 109.784 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.494 1.748 0 O-C-N 121.75 -0.593 . . . . 1.0600000000000001 109.749 -179.855 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.443 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 7.8 tp . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 108.882 -0.784 . . . . 1.24 108.882 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 50.9 mm-40 -63.1 -31.56 72.72 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.7 -0.625 . . . . 0.75 109.451 179.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.57 -30.57 75.05 Favored Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.595 -1.402 . . . . 0.51000000000000001 109.595 179.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 0.443 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.67 -38.11 26.4 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.281 -1.007 . . . . 0.70999999999999996 108.281 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.53 -48.11 73.61 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.519 -0.549 . . . . 0.67000000000000004 109.519 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.1 p -64.21 -36.67 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.61 -0.681 . . . . 1.1100000000000001 109.742 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.45 -48.9 63.33 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.57999999999999996 110.165 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.494 1.761 0 O-C-N 121.686 -0.634 . . . . 0.84999999999999998 110.338 -179.327 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.519 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 12.1 tp . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.62 -0.511 . . . . 1.3200000000000001 109.62 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 43.6 mm-40 -65.12 -30.37 71.3 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.562 -0.711 . . . . 0.88 110.022 179.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.81 -27.07 71.6 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.787 -1.325 . . . . 0.58999999999999997 109.787 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 0.519 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -80.16 -36.35 35.22 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.483 -1.01 . . . . 0.71999999999999997 108.462 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -69.86 -48.43 58.88 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.419 -0.586 . . . . 0.77000000000000002 109.419 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 28.3 m -62.51 -37.06 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.622 -0.673 . . . . 1.1899999999999999 109.7 179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -74.15 -49.45 23.65 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.735 -0.603 . . . . 0.46999999999999997 110.21 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.8 p . . . . . 0 N--CA 1.496 1.856 0 O-C-N 121.624 -0.673 . . . . 1.1499999999999999 109.951 -179.599 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.509 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.6 tp . . . . . 0 N--CA 1.492 1.635 0 N-CA-C 109.347 -0.612 . . . . 1.79 109.347 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 43.6 mm-40 -62.48 -30.94 71.63 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.673 -0.642 . . . . 1.0 109.785 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -31.01 75.47 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.583 -1.407 . . . . 1.04 109.583 179.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 0.509 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.37 -39.1 25.56 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 108.199 -1.037 . . . . 1.77 108.199 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.79 -43.56 95.98 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 109.551 -0.537 . . . . 1.03 109.551 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.5 -37.36 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.582 -0.699 . . . . 1.3300000000000001 109.738 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.01 -48.91 61.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.51 -0.744 . . . . 1.29 109.977 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.0 p . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.766 -0.584 . . . . 2.1800000000000002 110.286 -179.563 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.459 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 9.4 tp . . . . . 0 N--CA 1.491 1.624 0 N-CA-C 109.025 -0.731 . . . . 1.3200000000000001 109.025 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 39.5 mm-40 -64.54 -30.22 71.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.686 -0.634 . . . . 0.81000000000000005 109.467 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.43 -31.52 74.14 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.805 -1.318 . . . . 0.46000000000000002 109.805 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 0.459 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -77.19 -37.49 53.49 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.488 -1.007 . . . . 0.48999999999999999 108.619 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.6 -45.62 86.15 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.28 -0.637 . . . . 0.68999999999999995 109.28 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.3 p -74.72 -35.29 36.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.58 -0.7 . . . . 1.0900000000000001 109.639 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.78 -46.1 66.54 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.575 -0.703 . . . . 0.62 110.561 -179.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.494 1.747 0 O-C-N 121.517 -0.739 . . . . 1.27 109.618 -179.709 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.444 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.3 tp . . . . . 0 N--CA 1.492 1.648 0 N-CA-C 109.165 -0.68 . . . . 1.3300000000000001 109.165 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 42.1 mm-40 -62.62 -31.02 71.79 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.732 -0.605 . . . . 0.63 109.658 179.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.73 -31.91 76.95 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.478 -1.449 . . . . 0.42999999999999999 109.478 179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 0.444 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.8 m-85 -81.12 -38.59 26.97 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 108.228 -1.027 . . . . 0.63 108.228 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.27 -46.89 78.65 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.416 -0.587 . . . . 0.55000000000000004 109.416 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -66.49 -36.48 77.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.587 -0.695 . . . . 1.1200000000000001 109.711 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.73 -49.24 55.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.551 -0.718 . . . . 0.52000000000000002 109.979 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 1.1599999999999999 109.875 -179.794 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tp . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 108.629 -0.878 . . . . 1.25 108.629 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 47.0 mm-40 -65.72 -31.22 72.1 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.39 -0.596 . . . . 0.58999999999999997 109.39 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.88 -31.98 79.73 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 109.453 -1.459 . . . . 0.34000000000000002 109.453 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -80.01 -38.43 32.11 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.257 -1.016 . . . . 0.48999999999999999 108.257 178.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.97 -43.8 94.66 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 109.422 -0.585 . . . . 0.46999999999999997 109.422 179.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.6 p -72.16 -37.8 60.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.491 -0.756 . . . . 1.1399999999999999 109.521 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.76 -49.19 60.77 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.465 -0.772 . . . . 0.45000000000000001 109.998 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.737 -0.602 . . . . 1.04 110.008 -179.655 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tp . . . . . 0 N--CA 1.493 1.678 0 N-CA-C 109.354 -0.61 . . . . 1.1799999999999999 109.354 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 34.7 mm-40 -62.98 -31.56 72.71 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.72 -0.612 . . . . 0.60999999999999999 110.332 -179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.33 -34.58 90.33 Favored Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.606 -1.398 . . . . 0.26000000000000001 109.606 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -77.09 -38.33 52.57 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 108.328 -0.99 . . . . 0.46000000000000002 108.328 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.6 -44.07 83.14 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.986 -0.446 . . . . 0.5 109.94 179.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.6 p -73.83 -38.88 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.567 -0.708 . . . . 1.1599999999999999 110.077 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.37 -47.72 63.43 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.421 -0.799 . . . . 0.46000000000000002 110.03 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.2 p . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.382 -0.824 . . . . 0.96999999999999997 110.326 -179.701 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.8 tp . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 108.986 -0.746 . . . . 1.25 108.986 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 40.6 mm-40 -61.85 -31.98 72.28 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.653 -0.655 . . . . 0.66000000000000003 109.411 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.94 -30.1 76.38 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.428 -1.469 . . . . 0.51000000000000001 109.428 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -82.29 -36.95 26.52 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.56 -0.964 . . . . 0.80000000000000004 108.501 179.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.4 -42.92 99.8 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 109.063 -0.717 . . . . 0.63 109.063 178.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.8 p -76.27 -36.89 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.651 -0.656 . . . . 1.1200000000000001 109.33 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.48 -50.4 59.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.573 -0.705 . . . . 0.59999999999999998 109.704 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.496 1.844 0 O-C-N 121.686 -0.634 . . . . 1.1399999999999999 109.537 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.424 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 11.3 tp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.008 -0.738 . . . . 1.46 109.008 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 40.8 mm-40 -64.32 -31.99 73.42 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.688 -0.633 . . . . 0.79000000000000004 109.35 179.232 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.46 82.92 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.422 -1.471 . . . . 0.62 109.422 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' PHE . . . . . 0.424 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.6 m-85 -80.96 -37.16 29.87 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.191 -1.041 . . . . 0.85999999999999999 108.191 178.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.04 -46.79 76.6 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 109.599 -0.519 . . . . 0.76000000000000001 109.599 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.4 p -65.18 -37.26 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.613 -0.68 . . . . 1.22 109.89 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.05 -49.59 67.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.733 . . . . 0.57999999999999996 110.098 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.673 -0.642 . . . . 1.28 110.174 -179.525 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.733 0 CA-C-O 121.418 0.628 . . . . 2.6099999999999999 110.001 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.94 -81.86 0.04 OUTLIER Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.536 -1.426 . . . . 1.01 109.536 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 9.0 tp -150.89 56.31 0.9 Allowed 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.687 -0.89 . . . . 1.6299999999999999 109.674 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -85.55 -130.68 2.45 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.943 -1.263 . . . . 0.68999999999999995 109.943 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 33.2 t -85.4 -45.32 11.99 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.671 -0.899 . . . . 1.3200000000000001 110.179 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.49 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.4 t70 -76.08 -40.48 53.04 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.441 -0.787 . . . . 0.93000000000000005 110.033 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -63.89 -47.13 81.85 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.543 -0.723 . . . . 0.66000000000000003 109.637 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 21.7 ptt? -62.17 -39.72 93.62 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 108.553 -0.906 . . . . 1.3400000000000001 108.553 178.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.4 tp -60.64 -42.62 97.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.9 -0.778 . . . . 1.27 108.9 178.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.49 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 45.3 mm-40 -65.01 -31.74 73.12 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 109.234 -0.654 . . . . 0.71999999999999997 109.234 179.054 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -31.88 79.94 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.476 -1.45 . . . . 0.45000000000000001 109.476 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -80.18 -37.95 32.26 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.552 -0.969 . . . . 0.56000000000000005 108.401 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.86 -42.71 99.86 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 109.287 -0.634 . . . . 0.66000000000000003 109.287 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.5 p -74.32 -37.13 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.686 . . . . 1.1499999999999999 109.662 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.523 ' HB1' ' HA ' ' A' ' 23' ' ' ALA . . . -65.69 -51.14 61.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.523 -0.736 . . . . 0.54000000000000004 109.784 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p -64.24 -32.7 58.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.75 -0.593 . . . . 1.0600000000000001 109.749 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . 0.403 ' HA ' ' HD2' ' A' ' 17' ' ' LYS . 7.2 tptp -72.25 -40.07 67.97 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.498 -0.751 . . . . 1.3899999999999999 109.564 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mmt -77.2 -50.61 12.55 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.613 -0.68 . . . . 2.71 109.643 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.28 66.82 1.16 Allowed Glycine 0 N--CA 1.495 2.626 0 N-CA-C 109.671 -1.372 . . . . 0.87 109.671 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -140.68 -61.65 0.5 Allowed 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.651 -0.911 . . . . 1.1200000000000001 109.831 -179.892 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 14.7 t -145.64 -158.95 0.95 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.543 -0.723 . . . . 0.90000000000000002 109.945 -179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.4 pttm -70.42 -29.92 66.65 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.237 -0.914 . . . . 2.6400000000000001 110.654 -179.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.523 ' HA ' ' HB1' ' A' ' 15' ' ' ALA . . . -142.7 121.38 12.59 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.498 -0.751 . . . . 1.27 109.712 -179.819 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.436 ' HB2' ' HA ' ' A' ' 15' ' ' ALA . 29.3 m-20 . . . . . 0 N--CA 1.497 1.907 0 O-C-N 121.576 -0.702 . . . . 1.5700000000000001 109.675 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 109.574 -0.528 . . . . 1.48 109.574 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -114.71 -78.68 0.8 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.433 -1.467 . . . . 1.0800000000000001 109.433 179.758 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -153.36 126.84 8.67 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.738 -0.86 . . . . 2.1899999999999999 109.418 179.72 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.07 -132.48 1.71 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.834 -1.306 . . . . 0.72999999999999998 109.834 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 29.4 t -85.8 -46.17 10.91 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.698 -0.883 . . . . 1.46 110.063 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.467 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.3 t70 -81.78 -37.88 26.46 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.516 -0.74 . . . . 1.0 110.238 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -64.03 -44.04 93.77 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.399 -0.813 . . . . 0.92000000000000004 109.641 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.407 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 25.1 ptt? -62.98 -40.04 96.55 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.475 -0.935 . . . . 1.6499999999999999 108.475 178.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.443 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 7.8 tp -60.97 -42.88 99.2 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.882 -0.784 . . . . 1.24 108.882 178.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.467 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 50.9 mm-40 -63.1 -31.56 72.72 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.7 -0.625 . . . . 0.75 109.451 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.57 -30.57 75.05 Favored Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.595 -1.402 . . . . 0.51000000000000001 109.595 179.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.443 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.67 -38.11 26.4 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.281 -1.007 . . . . 0.70999999999999996 108.281 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.53 -48.11 73.61 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.519 -0.549 . . . . 0.67000000000000004 109.519 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.1 p -64.21 -36.67 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.61 -0.681 . . . . 1.1100000000000001 109.742 179.703 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.474 ' HB3' ' HA ' ' A' ' 21' ' ' THR . . . -68.45 -48.9 63.33 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.57999999999999996 110.165 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.7 p -70.87 -32.83 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.686 -0.634 . . . . 0.84999999999999998 110.338 -179.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.16 -41.38 63.96 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.471 -0.768 . . . . 1.3799999999999999 109.991 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 42.3 mmm -81.85 -35.06 29.77 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.556 -0.715 . . . . 1.9299999999999999 109.997 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 98.97 44.02 2.5 Favored Glycine 0 N--CA 1.496 2.7 0 N-CA-C 109.549 -1.42 . . . . 0.64000000000000001 109.549 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.443 ' HB3' ' HB1' ' A' ' 23' ' ' ALA . . . -158.42 105.42 1.88 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.731 -0.864 . . . . 0.84999999999999998 109.472 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.474 ' HA ' ' HB3' ' A' ' 15' ' ' ALA . 60.5 m -77.61 -39.45 45.39 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.561 -0.712 . . . . 1.8200000000000001 109.975 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.57 -46.48 54.16 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.46 -0.775 . . . . 2.4199999999999999 109.796 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.443 ' HB1' ' HB3' ' A' ' 20' ' ' ALA . . . -77.27 -77.99 0.14 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.748 -0.595 . . . . 1.3200000000000001 109.687 -179.893 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 . . . . . 0 N--CA 1.496 1.842 0 O-C-N 121.396 -0.815 . . . . 1.1299999999999999 109.581 179.992 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 121.112 0.482 . . . . 1.8999999999999999 109.724 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -87.19 74.9 2.23 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.482 -1.447 . . . . 0.97999999999999998 109.482 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.1 pp -53.95 141.75 26.87 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.75 -0.853 . . . . 1.75 110.094 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.36 -63.93 2.64 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 109.536 -1.426 . . . . 0.63 109.536 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 42.4 t -71.86 -45.22 62.12 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.926 -0.75 . . . . 1.28 110.179 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.408 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 2.1 m-20 -70.9 -38.87 73.01 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.407 -0.808 . . . . 1.28 109.756 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -65.46 -49.82 67.67 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.531 -0.731 . . . . 1.05 109.605 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 10.7 ptt? -63.55 -34.78 78.56 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.527 -0.733 . . . . 1.6200000000000001 109.355 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.519 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 12.1 tp -60.37 -40.45 90.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.86 -0.525 . . . . 1.3200000000000001 109.62 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.408 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 43.6 mm-40 -65.12 -30.37 71.3 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.562 -0.711 . . . . 0.88 110.022 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.81 -27.07 71.6 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.787 -1.325 . . . . 0.58999999999999997 109.787 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.519 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -80.16 -36.35 35.22 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.483 -1.01 . . . . 0.71999999999999997 108.462 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -69.86 -48.43 58.88 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.419 -0.586 . . . . 0.77000000000000002 109.419 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 28.3 m -62.51 -37.06 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.622 -0.673 . . . . 1.1899999999999999 109.7 179.637 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.4 ' HA ' ' O ' ' A' ' 24' ' ' ASP . . . -74.15 -49.45 23.65 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.735 -0.603 . . . . 0.46999999999999997 110.21 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.8 p -63.39 -33.81 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.624 -0.673 . . . . 1.1499999999999999 109.951 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.4 -37.5 71.51 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.521 -0.737 . . . . 1.6299999999999999 109.578 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 10.2 mmm -76.88 -51.17 11.74 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.52 -0.738 . . . . 2.29 109.53 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -166.8 -92.33 0.09 OUTLIER Glycine 0 N--CA 1.496 2.644 0 N-CA-C 110.011 -1.235 . . . . 0.68999999999999995 110.011 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.48 ' HB2' ' HB1' ' A' ' 23' ' ' ALA . . . -82.75 130.18 35.09 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.619 -0.93 . . . . 1.45 110.081 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.0 t -61.71 -22.45 65.36 Favored 'General case' 0 N--CA 1.503 2.184 0 O-C-N 121.741 -0.599 . . . . 1.3 110.839 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.99 33.32 5.7 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.188 -0.945 . . . . 1.3600000000000001 110.162 -179.831 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . 0.48 ' HB1' ' HB2' ' A' ' 20' ' ' ALA . . . -170.25 -93.59 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.975 0 O-C-N 121.22 -0.925 . . . . 1.4299999999999999 109.865 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.4 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 21.9 t70 . . . . . 0 N--CA 1.495 1.813 0 O-C-N 121.319 -0.863 . . . . 1.0600000000000001 109.51 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.156 0.503 . . . . 2.4300000000000002 109.733 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -119.28 111.62 2.11 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.576 -1.41 . . . . 1.24 109.576 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.2 pp -57.02 147.76 23.29 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.762 -0.846 . . . . 2.0099999999999998 110.024 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 94.02 -62.0 1.89 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.502 -1.439 . . . . 1.1299999999999999 109.502 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 44.0 t -70.52 -45.34 65.74 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.846 -0.796 . . . . 1.4299999999999999 110.245 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.407 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 7.8 m-20 -69.37 -42.41 75.25 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.482 -0.761 . . . . 1.24 109.723 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.65 -49.41 68.74 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.72 -0.612 . . . . 1.25 110.18 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 11.1 ptt? -61.43 -36.84 81.48 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.38 -0.825 . . . . 2.0299999999999998 109.517 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.509 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.6 tp -60.22 -41.09 92.32 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.347 -0.612 . . . . 1.79 109.347 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.407 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 43.6 mm-40 -62.48 -30.94 71.63 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.673 -0.642 . . . . 1.0 109.785 179.517 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -31.01 75.47 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.583 -1.407 . . . . 1.04 109.583 179.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.509 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.37 -39.1 25.56 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 108.199 -1.037 . . . . 1.77 108.199 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.79 -43.56 95.98 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 109.551 -0.537 . . . . 1.03 109.551 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.5 -37.36 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.582 -0.699 . . . . 1.3300000000000001 109.738 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.474 ' HA ' ' HB2' ' A' ' 24' ' ' ASP . . . -69.01 -48.91 61.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.51 -0.744 . . . . 1.29 109.977 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.0 p -66.56 -30.9 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.766 -0.584 . . . . 2.1800000000000002 110.286 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.68 -38.81 28.32 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.447 -0.783 . . . . 1.6100000000000001 110.436 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 63.0 mmm -65.21 -68.41 0.36 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.456 -0.777 . . . . 2.6400000000000001 110.104 -179.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 149.32 59.85 0.01 OUTLIER Glycine 0 N--CA 1.499 2.84 0 N-CA-C 110.093 -1.203 . . . . 1.53 110.093 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -133.07 155.97 48.24 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.748 -0.854 . . . . 1.4299999999999999 109.7 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.454 HG22 ' HD2' ' A' ' 22' ' ' LYS . 9.3 t -64.87 -38.19 90.15 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.451 -0.781 . . . . 2.79 109.972 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.454 ' HD2' HG22 ' A' ' 21' ' ' THR . 0.1 OUTLIER -143.37 -54.4 0.38 Allowed 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.439 -0.788 . . . . 3.75 109.717 179.913 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -119.26 129.22 54.81 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.758 -0.589 . . . . 2.5299999999999998 109.572 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.474 ' HB2' ' HA ' ' A' ' 15' ' ' ALA . 8.1 t70 . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.606 -0.684 . . . . 1.47 109.565 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.667 0 N-CA-C 109.547 -0.538 . . . . 2.9900000000000002 109.547 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.62 -95.53 1.88 Allowed Glycine 0 N--CA 1.495 2.606 0 N-CA-C 110.016 -1.234 . . . . 1.29 110.016 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.72 96.71 4.95 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.704 -0.88 . . . . 1.4299999999999999 109.994 -179.618 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 140.13 -100.08 0.27 Allowed Glycine 0 N--CA 1.495 2.606 0 N-CA-C 110.191 -1.164 . . . . 0.59999999999999998 110.191 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 33.1 t -61.74 -40.74 96.16 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.912 -0.757 . . . . 1.1299999999999999 110.847 -179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -79.9 -42.77 23.49 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.338 -0.851 . . . . 0.88 110.105 -179.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -64.99 -44.66 88.56 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.465 -0.772 . . . . 0.66000000000000003 110.148 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.43 ' HA ' ' CE ' ' A' ' 22' ' ' LYS . 17.2 ptt? -56.89 -41.68 78.49 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.327 -0.858 . . . . 1.6000000000000001 109.188 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.459 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 9.4 tp -60.79 -43.77 97.68 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.025 -0.731 . . . . 1.3200000000000001 109.025 179.033 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 39.5 mm-40 -64.54 -30.22 71.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.686 -0.634 . . . . 0.81000000000000005 109.467 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.43 -31.52 74.14 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.805 -1.318 . . . . 0.46000000000000002 109.805 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.459 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -77.19 -37.49 53.49 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.488 -1.007 . . . . 0.48999999999999999 108.619 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.6 -45.62 86.15 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.28 -0.637 . . . . 0.68999999999999995 109.28 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.3 p -74.72 -35.29 36.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.58 -0.7 . . . . 1.0900000000000001 109.639 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.441 ' HB2' ' C ' ' A' ' 20' ' ' ALA . . . -69.78 -46.1 66.54 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.575 -0.703 . . . . 0.62 110.561 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p -62.81 -31.76 53.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.517 -0.739 . . . . 1.27 109.618 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.83 -37.55 26.87 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.62 -0.675 . . . . 1.73 109.914 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 34.6 mmm -86.97 -66.47 0.9 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.403 -0.81 . . . . 2.23 110.074 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 148.76 70.14 0.01 OUTLIER Glycine 0 N--CA 1.498 2.784 0 N-CA-C 110.259 -1.136 . . . . 0.56999999999999995 110.259 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.441 ' C ' ' HB2' ' A' ' 15' ' ' ALA . . . -166.64 -159.87 0.38 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.581 -0.952 . . . . 0.89000000000000001 109.657 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 26.5 p -108.21 -73.56 0.68 Allowed 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.257 -0.902 . . . . 1.3200000000000001 109.471 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . 0.43 ' CE ' ' HA ' ' A' ' 8' ' ' MET . 0.0 OUTLIER -112.87 -27.33 8.15 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.523 -0.736 . . . . 0.91000000000000003 110.132 179.79 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -138.79 130.52 27.66 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.443 -0.785 . . . . 1.23 109.422 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 . . . . . 0 N--CA 1.495 1.805 0 O-C-N 121.586 -0.696 . . . . 1.21 109.53 -179.878 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.252 0.549 . . . . 1.54 109.536 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -109.12 97.04 1.03 Allowed Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.446 -1.461 . . . . 0.62 109.446 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 11.0 mt -57.96 107.01 0.42 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.743 -0.857 . . . . 1.78 109.818 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 141.47 -98.78 0.23 Allowed Glycine 0 N--CA 1.494 2.559 0 N-CA-C 109.9 -1.28 . . . . 0.51000000000000001 109.9 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 49.9 t -83.51 -38.97 21.06 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.811 -0.817 . . . . 1.3 110.453 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.469 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 28.2 t70 -71.76 -47.4 53.89 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.378 -0.826 . . . . 0.79000000000000004 109.817 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -64.51 -45.8 85.71 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.593 -0.692 . . . . 0.48999999999999999 110.231 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 11.8 ptt? -61.96 -39.79 93.37 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.307 -0.871 . . . . 1.6799999999999999 109.137 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.444 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.3 tp -60.83 -42.25 97.36 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 109.165 -0.68 . . . . 1.3300000000000001 109.165 179.173 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.469 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 42.1 mm-40 -62.62 -31.02 71.79 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.732 -0.605 . . . . 0.63 109.658 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.73 -31.91 76.95 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.478 -1.449 . . . . 0.42999999999999999 109.478 179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.444 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.8 m-85 -81.12 -38.59 26.97 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 108.228 -1.027 . . . . 0.63 108.228 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.27 -46.89 78.65 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.416 -0.587 . . . . 0.55000000000000004 109.416 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -66.49 -36.48 77.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.587 -0.695 . . . . 1.1200000000000001 109.711 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.73 -49.24 55.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.551 -0.718 . . . . 0.52000000000000002 109.979 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p -65.47 -34.25 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 1.1599999999999999 109.875 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.83 -40.57 65.64 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.521 -0.737 . . . . 1.5600000000000001 109.52 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 48.1 mtt -72.2 -50.54 26.74 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.632 -0.668 . . . . 2.5800000000000001 109.522 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 112.69 61.73 0.44 Allowed Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.867 -1.293 . . . . 0.69999999999999996 109.867 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.66 -54.34 8.35 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.708 -0.877 . . . . 1.3300000000000001 109.264 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 72.4 p -124.0 -56.02 1.67 Allowed 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.705 -0.622 . . . . 1.6299999999999999 109.465 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -178.97 -50.04 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 109.16 -0.681 . . . . 1.22 109.16 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -133.28 72.27 1.48 Allowed 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.633 -0.877 . . . . 1.3200000000000001 108.633 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.601 -0.687 . . . . 0.85999999999999999 109.678 -179.185 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 N-CA-C 109.248 -0.649 . . . . 1.3500000000000001 109.248 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 73.51 -161.85 54.32 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 109.903 -1.279 . . . . 0.93000000000000005 109.903 -179.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -161.59 143.23 11.45 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.451 -1.029 . . . . 1.9199999999999999 110.037 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.94 -117.04 0.75 Allowed Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.019 -1.633 . . . . 0.64000000000000001 109.019 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.408 ' O ' ' HG2' ' A' ' 8' ' ' MET . 40.4 t -85.73 -73.91 0.43 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.642 -0.917 . . . . 1.3100000000000001 108.789 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -88.22 -21.45 24.52 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.541 -0.724 . . . . 0.91000000000000003 109.584 179.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -66.17 -36.99 84.56 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.539 -0.725 . . . . 0.66000000000000003 110.113 -179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.408 ' HG2' ' O ' ' A' ' 5' ' ' CYS . 27.1 ptt? -58.78 -43.24 90.38 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.41 -0.807 . . . . 1.6399999999999999 109.181 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.404 ' N ' ' HG3' ' A' ' 8' ' ' MET . 9.2 tp -60.85 -42.16 97.29 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.629 -0.878 . . . . 1.25 108.629 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 47.0 mm-40 -65.72 -31.22 72.1 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.39 -0.596 . . . . 0.58999999999999997 109.39 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.88 -31.98 79.73 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 109.453 -1.459 . . . . 0.34000000000000002 109.453 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.578 ' HA ' ' HB2' ' A' ' 24' ' ' ASP . 2.9 m-85 -80.01 -38.43 32.11 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.257 -1.016 . . . . 0.48999999999999999 108.257 178.991 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.97 -43.8 94.66 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 109.422 -0.585 . . . . 0.46999999999999997 109.422 179.091 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.41 HG21 ' SD ' ' A' ' 18' ' ' MET . 11.6 p -72.16 -37.8 60.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.491 -0.756 . . . . 1.1399999999999999 109.521 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.76 -49.19 60.77 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.465 -0.772 . . . . 0.45000000000000001 109.998 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.5 p -60.91 -34.15 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.737 -0.602 . . . . 1.04 110.008 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -80.0 -37.53 33.98 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.505 -0.747 . . . . 2.9900000000000002 110.335 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' MET . . . . . 0.41 ' SD ' HG21 ' A' ' 14' ' ' VAL . 48.6 mtp -64.76 -56.84 11.11 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.431 -0.793 . . . . 2.52 110.075 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -175.43 87.51 0.08 OUTLIER Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.546 -1.422 . . . . 0.73999999999999999 109.546 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 178.62 127.81 0.06 Allowed 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.906 -0.761 . . . . 0.79000000000000004 109.703 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 21.2 p -71.21 -64.38 0.92 Allowed 'General case' 0 N--CA 1.499 1.978 0 N-CA-C 108.901 -0.777 . . . . 1.3700000000000001 108.901 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -139.05 15.75 2.64 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.605 -0.684 . . . . 1.25 110.434 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -92.15 66.04 4.81 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.199 -0.938 . . . . 1.4199999999999999 108.567 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.578 ' HB2' ' HA ' ' A' ' 12' ' ' PHE . 2.9 p-10 . . . . . 0 N--CA 1.494 1.735 0 O-C-N 121.652 -0.655 . . . . 1.45 109.673 -179.049 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.5 mm100 . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.457 -0.571 . . . . 1.3300000000000001 109.457 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -87.48 86.33 1.52 Allowed Glycine 0 N--CA 1.497 2.717 0 N-CA-C 109.778 -1.329 . . . . 0.68000000000000005 109.778 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.452 HD22 ' HA3' ' A' ' 11' ' ' GLY . 5.9 mp -74.71 94.06 2.66 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.748 -0.854 . . . . 1.23 109.573 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.4 -116.72 3.49 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.561 -1.416 . . . . 0.51000000000000001 109.561 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 50.5 t -86.04 -64.31 1.17 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.634 -0.921 . . . . 1.1899999999999999 109.468 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -78.63 -40.9 32.95 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.638 -0.664 . . . . 0.79000000000000004 110.016 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.448 ' HB3' ' HA ' ' A' ' 3' ' ' LEU . 1.0 OUTLIER -65.44 -22.37 66.75 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.47 -0.768 . . . . 0.47999999999999998 110.383 -179.802 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -55.93 -55.8 28.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.161 -0.962 . . . . 2.25 108.575 179.182 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tp -66.53 -40.58 89.2 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.716 -0.615 . . . . 1.1799999999999999 109.354 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.424 ' HB2' ' HA ' ' A' ' 7' ' ' GLU . 34.7 mm-40 -62.98 -31.56 72.71 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.72 -0.612 . . . . 0.60999999999999999 110.332 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.452 ' HA3' HD22 ' A' ' 3' ' ' LEU . . . -63.33 -34.58 90.33 Favored Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.606 -1.398 . . . . 0.26000000000000001 109.606 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -77.09 -38.33 52.57 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 108.328 -0.99 . . . . 0.46000000000000002 108.328 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.6 -44.07 83.14 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.986 -0.446 . . . . 0.5 109.94 179.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.6 p -73.83 -38.88 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.567 -0.708 . . . . 1.1599999999999999 110.077 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.484 ' HB3' ' HA ' ' A' ' 20' ' ' ALA . . . -69.37 -47.72 63.43 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.421 -0.799 . . . . 0.46000000000000002 110.03 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.2 p -63.5 -22.51 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.382 -0.824 . . . . 0.96999999999999997 110.326 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.3 -46.12 9.47 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.415 -0.803 . . . . 1.79 110.389 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mtt -88.66 -53.26 4.72 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.5 -0.75 . . . . 2.7000000000000002 110.224 -179.343 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 174.78 120.84 0.61 Allowed Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.479 -1.448 . . . . 0.38 109.479 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.484 ' HA ' ' HB3' ' A' ' 15' ' ' ALA . . . -65.1 103.4 0.75 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.742 -0.858 . . . . 1.1000000000000001 109.83 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 24.1 p -103.64 -63.17 1.21 Allowed 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.547 -0.721 . . . . 1.1899999999999999 109.618 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -145.67 31.59 1.06 Allowed 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.575 -0.703 . . . . 1.9099999999999999 110.246 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -160.39 87.68 0.77 Allowed 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.154 -0.966 . . . . 1.24 109.916 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.878 0 O-C-N 121.372 -0.83 . . . . 1.04 109.701 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.567 -0.531 . . . . 2.5099999999999998 109.567 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -114.35 57.6 0.46 Allowed Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.755 -1.338 . . . . 1.3300000000000001 109.755 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . 0.544 ' HA ' ' HB2' ' A' ' 7' ' ' GLU . 3.8 tp -141.88 89.23 2.17 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.624 -0.927 . . . . 1.5 109.671 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -99.2 -130.26 6.86 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.531 -1.427 . . . . 0.81000000000000005 109.531 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.9 t -85.65 -40.62 15.99 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.723 -0.869 . . . . 1.5900000000000001 110.123 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.48 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.6 t70 -79.43 -42.25 25.83 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.434 -0.791 . . . . 1.8200000000000001 110.325 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . 0.544 ' HB2' ' HA ' ' A' ' 3' ' ' LEU . 1.3 mp0 -63.64 -45.46 90.1 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.403 -0.81 . . . . 0.79000000000000004 109.652 -179.422 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.42 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 17.1 ptt? -61.59 -40.82 96.16 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 108.42 -0.956 . . . . 1.6200000000000001 108.42 178.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.42 ' N ' ' HG3' ' A' ' 8' ' ' MET . 9.8 tp -62.17 -45.63 92.55 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.986 -0.746 . . . . 1.25 108.986 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.48 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 40.6 mm-40 -61.85 -31.98 72.28 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.653 -0.655 . . . . 0.66000000000000003 109.411 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.94 -30.1 76.38 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.428 -1.469 . . . . 0.51000000000000001 109.428 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -82.29 -36.95 26.52 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.56 -0.964 . . . . 0.80000000000000004 108.501 179.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.4 -42.92 99.8 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 109.063 -0.717 . . . . 0.63 109.063 178.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.8 p -76.27 -36.89 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.651 -0.656 . . . . 1.1200000000000001 109.33 179.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.48 -50.4 59.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.573 -0.705 . . . . 0.59999999999999998 109.704 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p -60.52 -33.35 54.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.686 -0.634 . . . . 1.1399999999999999 109.537 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 6.5 tptp -64.82 -35.17 80.24 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 109.03 -0.729 . . . . 1.4299999999999999 109.03 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 75.5 mtp -84.58 -47.23 10.76 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.743 -0.598 . . . . 2.6899999999999999 109.428 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -168.53 -94.53 0.1 OUTLIER Glycine 0 N--CA 1.497 2.718 0 N-CA-C 110.282 -1.127 . . . . 0.54000000000000004 110.282 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -75.63 132.85 40.89 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.685 -0.891 . . . . 1.3400000000000001 110.5 -179.302 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 12.6 t -71.5 -32.66 68.47 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.594 -0.691 . . . . 1.5 110.269 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.68 -44.84 85.0 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.392 -0.818 . . . . 2.4900000000000002 109.936 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -168.12 124.44 1.05 Allowed 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 109.473 -0.566 . . . . 1.77 109.473 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.3 t70 . . . . . 0 N--CA 1.495 1.786 0 O-C-N 121.628 -0.67 . . . . 1.1699999999999999 109.68 -179.883 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 N-CA-C 109.671 -0.492 . . . . 2.8700000000000001 109.671 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -140.05 91.09 0.19 Allowed Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.555 -1.418 . . . . 1.0800000000000001 109.555 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.4 tp -60.99 108.06 0.81 Allowed 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.701 -0.882 . . . . 2.5499999999999998 109.732 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 139.1 -90.57 0.19 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.736 -1.346 . . . . 0.80000000000000004 109.736 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 45.4 t -85.69 -41.04 15.5 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.81 -0.818 . . . . 1.3 110.43 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.45 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 11.0 m-20 -73.43 -46.43 48.56 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.439 -0.788 . . . . 0.97999999999999998 110.117 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.73 -44.5 89.97 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.575 -0.703 . . . . 0.88 110.1 -179.484 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' MET . . . . . 0.41 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 14.8 ptt? -61.87 -40.04 93.99 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.365 -0.835 . . . . 1.8500000000000001 108.878 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.424 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 11.3 tp -60.7 -42.05 96.42 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.008 -0.738 . . . . 1.46 109.008 179.031 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLN . . . . . 0.45 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 40.8 mm-40 -64.32 -31.99 73.42 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.688 -0.633 . . . . 0.79000000000000004 109.35 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.46 82.92 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.422 -1.471 . . . . 0.62 109.422 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.424 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.6 m-85 -80.96 -37.16 29.87 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.191 -1.041 . . . . 0.85999999999999999 108.191 178.918 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.04 -46.79 76.6 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 109.599 -0.519 . . . . 0.76000000000000001 109.599 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.4 p -65.18 -37.26 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.613 -0.68 . . . . 1.22 109.89 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ALA . . . . . 0.406 ' HA ' ' CB ' ' A' ' 24' ' ' ASP . . . -66.05 -49.59 67.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.733 . . . . 0.57999999999999996 110.098 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.17 -32.88 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.673 -0.642 . . . . 1.28 110.174 -179.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.29 -40.55 67.49 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.466 -0.772 . . . . 1.3100000000000001 110.0 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 32.5 mmm -80.23 -40.35 27.25 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.58 -0.7 . . . . 1.8600000000000001 109.777 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 99.79 48.26 1.66 Allowed Glycine 0 N--CA 1.496 2.685 0 N-CA-C 109.535 -1.426 . . . . 0.81999999999999995 109.535 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -149.45 120.95 7.95 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.602 -0.94 . . . . 1.24 109.724 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 20.3 p -82.52 -58.87 2.73 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.586 -0.696 . . . . 2.3900000000000001 109.546 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.69 63.77 8.24 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.536 -0.727 . . . . 2.9399999999999999 109.307 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -179.85 -81.9 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.647 -0.658 . . . . 1.6299999999999999 109.575 -179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . 0.406 ' CB ' ' HA ' ' A' ' 15' ' ' ALA . 9.7 m-20 . . . . . 0 N--CA 1.496 1.836 0 O-C-N 121.411 -0.806 . . . . 1.6000000000000001 109.612 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.4 tp . . . . . 0 N--CA 1.492 1.647 0 N-CA-C 108.9 -0.778 . . . . 0.59 108.9 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 45.3 mm-40 -65.01 -31.74 73.12 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 109.234 -0.654 . . . . 0.72 109.234 179.054 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -31.88 79.94 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.476 -1.45 . . . . 0.4 109.476 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -80.18 -37.95 32.26 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.552 -0.969 . . . . 0.5 108.401 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.86 -42.71 99.86 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 109.287 -0.634 . . . . 0.44 109.287 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.5 p -74.32 -37.13 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.686 . . . . 0.43 109.662 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.69 -51.14 61.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.523 -0.736 . . . . 0.32 109.784 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.494 1.748 0 O-C-N 121.75 -0.593 . . . . 0.5 109.749 -179.855 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.445 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 7.8 tp . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 108.882 -0.784 . . . . 0.66 108.882 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.4 ' O ' HG12 ' A' ' 14' ' ' VAL . 50.9 mm-40 -63.1 -31.56 72.72 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.7 -0.625 . . . . 0.72 109.451 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.57 -30.57 75.05 Favored Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.595 -1.402 . . . . 0.5 109.595 179.394 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.445 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.67 -38.11 26.4 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.281 -1.007 . . . . 0.64 108.281 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.53 -48.11 73.61 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.519 -0.549 . . . . 0.52 109.519 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 10' ' ' GLN . 12.1 p -64.21 -36.67 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.61 -0.681 . . . . 0.45 109.742 179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.45 -48.9 63.33 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.41 110.165 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.494 1.761 0 O-C-N 121.686 -0.634 . . . . 0.61 110.338 -179.327 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 12.1 tp . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.62 -0.511 . . . . 0.76 109.62 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.405 ' O ' HG13 ' A' ' 14' ' ' VAL . 43.6 mm-40 -65.12 -30.37 71.3 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.562 -0.711 . . . . 0.88 110.022 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.81 -27.07 71.6 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.787 -1.325 . . . . 0.53 109.787 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.536 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -80.16 -36.35 35.22 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.483 -1.01 . . . . 0.66 108.462 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -69.86 -48.43 58.88 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.419 -0.586 . . . . 0.54 109.419 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 15' ' ' ALA . 28.3 m -62.51 -37.06 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.622 -0.673 . . . . 0.62 109.7 179.637 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ALA . . . . . 0.41 ' N ' HG23 ' A' ' 14' ' ' VAL . . . -74.15 -49.45 23.65 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.735 -0.603 . . . . 0.34 110.21 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.8 p . . . . . 0 N--CA 1.496 1.856 0 O-C-N 121.624 -0.673 . . . . 0.54 109.951 -179.599 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.518 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.6 tp . . . . . 0 N--CA 1.492 1.635 0 N-CA-C 109.347 -0.612 . . . . 1.27 109.347 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 43.6 mm-40 -62.48 -30.94 71.63 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.673 -0.642 . . . . 0.94 109.785 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -31.01 75.47 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.583 -1.407 . . . . 1.02 109.583 179.355 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.518 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.37 -39.1 25.56 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 108.199 -1.037 . . . . 1.64 108.199 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.79 -43.56 95.98 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 109.551 -0.537 . . . . 0.82 109.551 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.5 -37.36 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.582 -0.699 . . . . 0.73 109.738 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.01 -48.91 61.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.51 -0.744 . . . . 1.15 109.977 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.0 p . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.766 -0.584 . . . . 1.42 110.286 -179.563 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.464 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 9.4 tp . . . . . 0 N--CA 1.491 1.624 0 N-CA-C 109.025 -0.731 . . . . 0.66 109.025 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 39.5 mm-40 -64.54 -30.22 71.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.686 -0.634 . . . . 0.81 109.467 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.43 -31.52 74.14 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.805 -1.318 . . . . 0.41 109.805 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.464 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -77.19 -37.49 53.49 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.488 -1.007 . . . . 0.44 108.619 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.6 -45.62 86.15 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.28 -0.637 . . . . 0.44 109.28 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.3 p -74.72 -35.29 36.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.58 -0.7 . . . . 0.47 109.639 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.78 -46.1 66.54 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.575 -0.703 . . . . 0.45 110.561 -179.648 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.494 1.747 0 O-C-N 121.517 -0.739 . . . . 0.62 109.618 -179.709 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.45 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.3 tp . . . . . 0 N--CA 1.492 1.648 0 N-CA-C 109.165 -0.68 . . . . 0.61 109.165 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 42.1 mm-40 -62.62 -31.02 71.79 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.732 -0.605 . . . . 0.61 109.658 179.498 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.73 -31.91 76.95 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.478 -1.449 . . . . 0.43 109.478 179.327 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.45 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.8 m-85 -81.12 -38.59 26.97 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 108.228 -1.027 . . . . 0.58 108.228 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.27 -46.89 78.65 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.416 -0.587 . . . . 0.39 109.416 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -66.49 -36.48 77.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.587 -0.695 . . . . 0.43 109.711 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.73 -49.24 55.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.551 -0.718 . . . . 0.42 109.979 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 0.48 109.875 -179.794 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tp . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 108.629 -0.878 . . . . 0.62 108.629 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 47.0 mm-40 -65.72 -31.22 72.1 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.39 -0.596 . . . . 0.56 109.39 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.88 -31.98 79.73 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 109.453 -1.459 . . . . 0.34 109.453 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -80.01 -38.43 32.11 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.257 -1.016 . . . . 0.43 108.257 178.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.97 -43.8 94.66 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 109.422 -0.585 . . . . 0.38 109.422 179.091 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.6 p -72.16 -37.8 60.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.491 -0.756 . . . . 0.45 109.521 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.76 -49.19 60.77 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.465 -0.772 . . . . 0.31 109.998 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.737 -0.602 . . . . 0.39 110.008 -179.655 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tp . . . . . 0 N--CA 1.493 1.678 0 N-CA-C 109.354 -0.61 . . . . 0.55 109.354 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.424 ' O ' HG12 ' A' ' 14' ' ' VAL . 34.7 mm-40 -62.98 -31.56 72.71 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.72 -0.612 . . . . 0.59 110.332 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.33 -34.58 90.33 Favored Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.606 -1.398 . . . . 0.26 109.606 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -77.09 -38.33 52.57 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 108.328 -0.99 . . . . 0.39 108.328 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.6 -44.07 83.14 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.986 -0.446 . . . . 0.36 109.94 179.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 10' ' ' GLN . 11.6 p -73.83 -38.88 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.567 -0.708 . . . . 0.46 110.077 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.37 -47.72 63.43 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.421 -0.799 . . . . 0.26 110.03 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.2 p . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.382 -0.824 . . . . 0.36 110.326 -179.701 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.8 tp . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 108.986 -0.746 . . . . 0.65 108.986 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.4 ' O ' HG12 ' A' ' 14' ' ' VAL . 40.6 mm-40 -61.85 -31.98 72.28 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.653 -0.655 . . . . 0.6 109.411 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.94 -30.1 76.38 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.428 -1.469 . . . . 0.51 109.428 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -82.29 -36.95 26.52 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.56 -0.964 . . . . 0.71 108.501 179.078 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.4 -42.92 99.8 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 109.063 -0.717 . . . . 0.46 109.063 178.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 10' ' ' GLN . 14.8 p -76.27 -36.89 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.651 -0.656 . . . . 0.62 109.33 179.223 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.48 -50.4 59.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.573 -0.705 . . . . 0.43 109.704 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.496 1.844 0 O-C-N 121.686 -0.634 . . . . 0.51 109.537 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.43 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 11.3 tp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.008 -0.738 . . . . 0.85 109.008 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLN . . . . . 0.419 ' O ' HG12 ' A' ' 14' ' ' VAL . 40.8 mm-40 -64.32 -31.99 73.42 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.688 -0.633 . . . . 0.76 109.35 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.46 82.92 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.422 -1.471 . . . . 0.62 109.422 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' PHE . . . . . 0.43 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.6 m-85 -80.96 -37.16 29.87 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.191 -1.041 . . . . 0.81 108.191 178.918 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.04 -46.79 76.6 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 109.599 -0.519 . . . . 0.59 109.599 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.419 HG12 ' O ' ' A' ' 10' ' ' GLN . 14.4 p -65.18 -37.26 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.613 -0.68 . . . . 0.61 109.89 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.05 -49.59 67.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.733 . . . . 0.5 110.098 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.673 -0.642 . . . . 0.65 110.174 -179.525 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.733 0 CA-C-O 121.418 0.628 . . . . 2.13 110.001 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.94 -81.86 0.04 OUTLIER Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.536 -1.426 . . . . 0.85 109.536 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 9.0 tp -150.89 56.31 0.9 Allowed 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.687 -0.89 . . . . 1.15 109.674 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -85.55 -130.68 2.45 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.943 -1.263 . . . . 0.55 109.943 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 33.2 t -85.4 -45.32 11.99 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.671 -0.899 . . . . 0.93 110.179 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.494 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.4 t70 -76.08 -40.48 53.04 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.441 -0.787 . . . . 0.93 110.033 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -63.89 -47.13 81.85 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.543 -0.723 . . . . 0.66 109.637 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.402 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 21.7 ptt? -62.17 -39.72 93.62 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 108.553 -0.906 . . . . 0.76 108.553 178.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.402 ' N ' ' HG3' ' A' ' 8' ' ' MET . 9.4 tp -60.64 -42.62 97.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.9 -0.778 . . . . 0.59 108.9 178.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.494 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 45.3 mm-40 -65.01 -31.74 73.12 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 109.234 -0.654 . . . . 0.72 109.234 179.054 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -31.88 79.94 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.476 -1.45 . . . . 0.4 109.476 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -80.18 -37.95 32.26 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.552 -0.969 . . . . 0.5 108.401 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.86 -42.71 99.86 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 109.287 -0.634 . . . . 0.44 109.287 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.5 p -74.32 -37.13 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.686 . . . . 0.43 109.662 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.581 ' HB2' ' HA ' ' A' ' 23' ' ' ALA . . . -65.69 -51.14 61.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.523 -0.736 . . . . 0.32 109.784 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p -64.24 -32.7 58.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.75 -0.593 . . . . 0.5 109.749 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LYS . . . . . 0.41 ' HA ' ' HD2' ' A' ' 17' ' ' LYS . 7.2 tptp -72.25 -40.07 67.97 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.498 -0.751 . . . . 1.04 109.564 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mmt -77.2 -50.61 12.55 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.613 -0.68 . . . . 2.18 109.643 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.28 66.82 1.16 Allowed Glycine 0 N--CA 1.495 2.626 0 N-CA-C 109.671 -1.372 . . . . 0.87 109.671 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.505 ' HB3' ' CG ' ' A' ' 24' ' ' ASP . . . -140.68 -61.65 0.5 Allowed 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.651 -0.911 . . . . 0.92 109.831 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.702 HG23 ' H ' ' A' ' 23' ' ' ALA . 14.7 t -145.64 -158.95 0.95 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.543 -0.723 . . . . 0.65 109.945 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.4 pttm -70.42 -29.92 66.65 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.237 -0.914 . . . . 2.17 110.654 -179.487 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.702 ' H ' HG23 ' A' ' 21' ' ' THR . . . -142.7 121.38 12.59 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.498 -0.751 . . . . 1.04 109.712 -179.819 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.521 ' OD1' HG22 ' A' ' 21' ' ' THR . 29.3 m-20 . . . . . 0 N--CA 1.497 1.907 0 O-C-N 121.576 -0.702 . . . . 1.57 109.675 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 109.574 -0.528 . . . . 0.97 109.574 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -114.71 -78.68 0.8 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.433 -1.467 . . . . 0.94 109.433 179.758 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -153.36 126.84 8.67 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.738 -0.86 . . . . 1.67 109.418 179.72 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.07 -132.48 1.71 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.834 -1.306 . . . . 0.62 109.834 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 29.4 t -85.8 -46.17 10.91 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.698 -0.883 . . . . 1.13 110.063 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.47 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.3 t70 -81.78 -37.88 26.46 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.516 -0.74 . . . . 1.0 110.238 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -64.03 -44.04 93.77 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.399 -0.813 . . . . 0.92 109.641 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.426 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 25.1 ptt? -62.98 -40.04 96.55 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.475 -0.935 . . . . 1.08 108.475 178.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.445 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 7.8 tp -60.97 -42.88 99.2 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.882 -0.784 . . . . 0.66 108.882 178.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.47 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 50.9 mm-40 -63.1 -31.56 72.72 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.7 -0.625 . . . . 0.72 109.451 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.57 -30.57 75.05 Favored Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.595 -1.402 . . . . 0.5 109.595 179.394 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.445 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.67 -38.11 26.4 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.281 -1.007 . . . . 0.64 108.281 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.53 -48.11 73.61 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.519 -0.549 . . . . 0.52 109.519 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 10' ' ' GLN . 12.1 p -64.21 -36.67 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.61 -0.681 . . . . 0.45 109.742 179.703 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.444 ' HB1' ' HA ' ' A' ' 21' ' ' THR . . . -68.45 -48.9 63.33 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.41 110.165 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.7 p -70.87 -32.83 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.686 -0.634 . . . . 0.61 110.338 -179.327 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.16 -41.38 63.96 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.471 -0.768 . . . . 1.06 109.991 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 42.3 mmm -81.85 -35.06 29.77 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.556 -0.715 . . . . 1.41 109.997 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 98.97 44.02 2.5 Favored Glycine 0 N--CA 1.496 2.7 0 N-CA-C 109.549 -1.42 . . . . 0.64 109.549 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -158.42 105.42 1.88 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.731 -0.864 . . . . 0.85 109.472 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.444 ' HA ' ' HB1' ' A' ' 15' ' ' ALA . 60.5 m -77.61 -39.45 45.39 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.561 -0.712 . . . . 1.36 109.975 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.57 -46.48 54.16 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.46 -0.775 . . . . 2.1 109.796 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -77.27 -77.99 0.14 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.748 -0.595 . . . . 0.85 109.687 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.417 ' HB2' ' HA ' ' A' ' 15' ' ' ALA . 8.3 m-20 . . . . . 0 N--CA 1.496 1.842 0 O-C-N 121.396 -0.815 . . . . 1.13 109.581 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 121.112 0.482 . . . . 1.53 109.724 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -87.19 74.9 2.23 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.482 -1.447 . . . . 0.85 109.482 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.1 pp -53.95 141.75 26.87 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.75 -0.853 . . . . 1.27 110.094 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.36 -63.93 2.64 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 109.536 -1.426 . . . . 0.52 109.536 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 42.4 t -71.86 -45.22 62.12 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.926 -0.75 . . . . 0.9 110.179 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.415 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 2.1 m-20 -70.9 -38.87 73.01 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.407 -0.808 . . . . 1.28 109.756 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -65.46 -49.82 67.67 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.531 -0.731 . . . . 1.05 109.605 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 10.7 ptt? -63.55 -34.78 78.56 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.527 -0.733 . . . . 1.07 109.355 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 12.1 tp -60.37 -40.45 90.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.86 -0.525 . . . . 0.76 109.62 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.415 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 43.6 mm-40 -65.12 -30.37 71.3 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.562 -0.711 . . . . 0.88 110.022 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.81 -27.07 71.6 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.787 -1.325 . . . . 0.53 109.787 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.536 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -80.16 -36.35 35.22 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.483 -1.01 . . . . 0.66 108.462 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -69.86 -48.43 58.88 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.419 -0.586 . . . . 0.54 109.419 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 15' ' ' ALA . 28.3 m -62.51 -37.06 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.622 -0.673 . . . . 0.62 109.7 179.637 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' A' ' 20' ' ' ALA . . . -74.15 -49.45 23.65 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.735 -0.603 . . . . 0.34 110.21 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.8 p -63.39 -33.81 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.624 -0.673 . . . . 0.54 109.951 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.4 -37.5 71.51 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.521 -0.737 . . . . 1.17 109.578 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 10.2 mmm -76.88 -51.17 11.74 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.52 -0.738 . . . . 1.77 109.53 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -166.8 -92.33 0.09 OUTLIER Glycine 0 N--CA 1.496 2.644 0 N-CA-C 110.011 -1.235 . . . . 0.64 110.011 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.562 ' O ' ' HB1' ' A' ' 15' ' ' ALA . . . -82.75 130.18 35.09 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.619 -0.93 . . . . 0.79 110.081 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.913 HG23 ' HD2' ' A' ' 22' ' ' LYS . 5.0 t -61.71 -22.45 65.36 Favored 'General case' 0 N--CA 1.503 2.184 0 O-C-N 121.741 -0.599 . . . . 0.74 110.839 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.913 ' HD2' HG23 ' A' ' 21' ' ' THR . 0.0 OUTLIER -118.99 33.32 5.7 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.188 -0.945 . . . . 1.06 110.162 -179.831 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.485 ' HB3' ' HB3' ' A' ' 20' ' ' ALA . . . -170.25 -93.59 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.975 0 O-C-N 121.22 -0.925 . . . . 1.02 109.865 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.411 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 21.9 t70 . . . . . 0 N--CA 1.495 1.813 0 O-C-N 121.319 -0.863 . . . . 1.06 109.51 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.156 0.503 . . . . 2.43 109.733 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -119.28 111.62 2.11 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.576 -1.41 . . . . 1.1 109.576 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.2 pp -57.02 147.76 23.29 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.762 -0.846 . . . . 1.45 110.024 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 94.02 -62.0 1.89 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.502 -1.439 . . . . 0.94 109.502 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 44.0 t -70.52 -45.34 65.74 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.846 -0.796 . . . . 1.3 110.245 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.419 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 7.8 m-20 -69.37 -42.41 75.25 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.482 -0.761 . . . . 1.24 109.723 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.65 -49.41 68.74 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.72 -0.612 . . . . 1.25 110.18 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 11.1 ptt? -61.43 -36.84 81.48 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.38 -0.825 . . . . 1.66 109.517 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.518 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.6 tp -60.22 -41.09 92.32 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.347 -0.612 . . . . 1.27 109.347 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.419 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 43.6 mm-40 -62.48 -30.94 71.63 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.673 -0.642 . . . . 0.94 109.785 179.517 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -31.01 75.47 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.583 -1.407 . . . . 1.02 109.583 179.355 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.518 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.37 -39.1 25.56 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 108.199 -1.037 . . . . 1.64 108.199 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.79 -43.56 95.98 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 109.551 -0.537 . . . . 0.82 109.551 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.5 -37.36 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.582 -0.699 . . . . 0.73 109.738 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.504 ' HA ' ' HB2' ' A' ' 24' ' ' ASP . . . -69.01 -48.91 61.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.51 -0.744 . . . . 1.15 109.977 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.0 p -66.56 -30.9 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.766 -0.584 . . . . 1.42 110.286 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.68 -38.81 28.32 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.447 -0.783 . . . . 1.22 110.436 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 63.0 mmm -65.21 -68.41 0.36 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.456 -0.777 . . . . 2.14 110.104 -179.333 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 149.32 59.85 0.01 OUTLIER Glycine 0 N--CA 1.499 2.84 0 N-CA-C 110.093 -1.203 . . . . 1.18 110.093 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -133.07 155.97 48.24 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.748 -0.854 . . . . 1.3 109.7 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.408 HG23 ' HD2' ' A' ' 22' ' ' LYS . 9.3 t -64.87 -38.19 90.15 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.451 -0.781 . . . . 2.59 109.972 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.408 ' HD2' HG23 ' A' ' 21' ' ' THR . 0.1 OUTLIER -143.37 -54.4 0.38 Allowed 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.439 -0.788 . . . . 3.37 109.717 179.913 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -119.26 129.22 54.81 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.758 -0.589 . . . . 1.89 109.572 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.504 ' HB2' ' HA ' ' A' ' 15' ' ' ALA . 8.1 t70 . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.606 -0.684 . . . . 1.47 109.565 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.667 0 N-CA-C 109.547 -0.538 . . . . 2.82 109.547 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.62 -95.53 1.88 Allowed Glycine 0 N--CA 1.495 2.606 0 N-CA-C 110.016 -1.234 . . . . 1.12 110.016 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.72 96.71 4.95 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.704 -0.88 . . . . 0.97 109.994 -179.618 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 140.13 -100.08 0.27 Allowed Glycine 0 N--CA 1.495 2.606 0 N-CA-C 110.191 -1.164 . . . . 0.45 110.191 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' O ' ' HG2' ' A' ' 8' ' ' MET . 33.1 t -61.74 -40.74 96.16 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.912 -0.757 . . . . 0.74 110.847 -179.223 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.409 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.4 m-20 -79.9 -42.77 23.49 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.338 -0.851 . . . . 0.88 110.105 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -64.99 -44.66 88.56 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.465 -0.772 . . . . 0.66 110.148 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.435 ' HA ' ' CE ' ' A' ' 22' ' ' LYS . 17.2 ptt? -56.89 -41.68 78.49 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.327 -0.858 . . . . 1.02 109.188 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.464 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 9.4 tp -60.79 -43.77 97.68 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.025 -0.731 . . . . 0.66 109.025 179.033 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.409 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 39.5 mm-40 -64.54 -30.22 71.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.686 -0.634 . . . . 0.81 109.467 179.204 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.43 -31.52 74.14 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.805 -1.318 . . . . 0.41 109.805 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.464 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -77.19 -37.49 53.49 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.488 -1.007 . . . . 0.44 108.619 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.6 -45.62 86.15 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.28 -0.637 . . . . 0.44 109.28 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.3 p -74.72 -35.29 36.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.58 -0.7 . . . . 0.47 109.639 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.455 ' HB1' ' C ' ' A' ' 20' ' ' ALA . . . -69.78 -46.1 66.54 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.575 -0.703 . . . . 0.45 110.561 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p -62.81 -31.76 53.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.517 -0.739 . . . . 0.62 109.618 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.83 -37.55 26.87 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.62 -0.675 . . . . 1.37 109.914 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 34.6 mmm -86.97 -66.47 0.9 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.403 -0.81 . . . . 1.79 110.074 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 148.76 70.14 0.01 OUTLIER Glycine 0 N--CA 1.498 2.784 0 N-CA-C 110.259 -1.136 . . . . 0.55 110.259 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.455 ' C ' ' HB1' ' A' ' 15' ' ' ALA . . . -166.64 -159.87 0.38 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.581 -0.952 . . . . 0.41 109.657 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 26.5 p -108.21 -73.56 0.68 Allowed 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.257 -0.902 . . . . 0.75 109.471 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.435 ' CE ' ' HA ' ' A' ' 8' ' ' MET . 0.0 OUTLIER -112.87 -27.33 8.15 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.523 -0.736 . . . . 0.62 110.132 179.79 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -138.79 130.52 27.66 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.443 -0.785 . . . . 0.71 109.422 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 . . . . . 0 N--CA 1.495 1.805 0 O-C-N 121.586 -0.696 . . . . 1.21 109.53 -179.878 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.252 0.549 . . . . 1.19 109.536 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -109.12 97.04 1.03 Allowed Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.446 -1.461 . . . . 0.5 109.446 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 11.0 mt -57.96 107.01 0.42 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.743 -0.857 . . . . 1.24 109.818 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 141.47 -98.78 0.23 Allowed Glycine 0 N--CA 1.494 2.559 0 N-CA-C 109.9 -1.28 . . . . 0.51 109.9 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 49.9 t -83.51 -38.97 21.06 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.811 -0.817 . . . . 0.88 110.453 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.474 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 28.2 t70 -71.76 -47.4 53.89 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.378 -0.826 . . . . 0.79 109.817 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -64.51 -45.8 85.71 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.593 -0.692 . . . . 0.49 110.231 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.407 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 11.8 ptt? -61.96 -39.79 93.37 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.307 -0.871 . . . . 0.98 109.137 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.45 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.3 tp -60.83 -42.25 97.36 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 109.165 -0.68 . . . . 0.61 109.165 179.173 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.474 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 42.1 mm-40 -62.62 -31.02 71.79 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.732 -0.605 . . . . 0.61 109.658 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.73 -31.91 76.95 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.478 -1.449 . . . . 0.43 109.478 179.327 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.45 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.8 m-85 -81.12 -38.59 26.97 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 108.228 -1.027 . . . . 0.58 108.228 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.27 -46.89 78.65 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.416 -0.587 . . . . 0.39 109.416 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -66.49 -36.48 77.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.587 -0.695 . . . . 0.43 109.711 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.73 -49.24 55.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.551 -0.718 . . . . 0.42 109.979 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p -65.47 -34.25 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 0.48 109.875 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.83 -40.57 65.64 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.521 -0.737 . . . . 1.16 109.52 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 48.1 mtt -72.2 -50.54 26.74 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.632 -0.668 . . . . 2.11 109.522 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 112.69 61.73 0.44 Allowed Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.867 -1.293 . . . . 0.57 109.867 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.66 -54.34 8.35 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.708 -0.877 . . . . 0.78 109.264 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.411 ' HB ' ' HE2' ' A' ' 22' ' ' LYS . 72.4 p -124.0 -56.02 1.67 Allowed 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.705 -0.622 . . . . 0.96 109.465 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.411 ' HE2' ' HB ' ' A' ' 21' ' ' THR . 0.0 OUTLIER -178.97 -50.04 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 109.16 -0.681 . . . . 1.01 109.16 179.846 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -133.28 72.27 1.48 Allowed 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.633 -0.877 . . . . 1.18 108.633 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.601 -0.687 . . . . 0.86 109.678 -179.185 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 N-CA-C 109.248 -0.649 . . . . 1.08 109.248 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 73.51 -161.85 54.32 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 109.903 -1.279 . . . . 0.79 109.903 -179.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.402 ' C ' ' HB2' ' A' ' 7' ' ' GLU . 0.6 OUTLIER -161.59 143.23 11.45 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.451 -1.029 . . . . 1.42 110.037 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.94 -117.04 0.75 Allowed Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.019 -1.633 . . . . 0.52 109.019 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' O ' ' HG2' ' A' ' 8' ' ' MET . 40.4 t -85.73 -73.91 0.43 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.642 -0.917 . . . . 0.8 108.789 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -88.22 -21.45 24.52 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.541 -0.724 . . . . 0.91 109.584 179.032 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.402 ' HB2' ' C ' ' A' ' 3' ' ' LEU . 1.2 mp0 -66.17 -36.99 84.56 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.539 -0.725 . . . . 0.66 110.113 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.423 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 27.1 ptt? -58.78 -43.24 90.38 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.41 -0.807 . . . . 0.97 109.181 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.423 ' N ' ' HG3' ' A' ' 8' ' ' MET . 9.2 tp -60.85 -42.16 97.29 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.629 -0.878 . . . . 0.62 108.629 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 47.0 mm-40 -65.72 -31.22 72.1 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.39 -0.596 . . . . 0.56 109.39 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.88 -31.98 79.73 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 109.453 -1.459 . . . . 0.34 109.453 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.596 ' HA ' ' HB2' ' A' ' 24' ' ' ASP . 2.9 m-85 -80.01 -38.43 32.11 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.257 -1.016 . . . . 0.43 108.257 178.991 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.97 -43.8 94.66 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 109.422 -0.585 . . . . 0.38 109.422 179.091 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.42 HG22 ' SD ' ' A' ' 18' ' ' MET . 11.6 p -72.16 -37.8 60.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.491 -0.756 . . . . 0.45 109.521 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.76 -49.19 60.77 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.465 -0.772 . . . . 0.31 109.998 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.5 p -60.91 -34.15 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.737 -0.602 . . . . 0.39 110.008 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -80.0 -37.53 33.98 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.505 -0.747 . . . . 2.42 110.335 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' MET . . . . . 0.42 ' SD ' HG22 ' A' ' 14' ' ' VAL . 48.6 mtp -64.76 -56.84 11.11 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.431 -0.793 . . . . 1.98 110.075 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -175.43 87.51 0.08 OUTLIER Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.546 -1.422 . . . . 0.74 109.546 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 178.62 127.81 0.06 Allowed 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.906 -0.761 . . . . 0.48 109.703 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 21.2 p -71.21 -64.38 0.92 Allowed 'General case' 0 N--CA 1.499 1.978 0 N-CA-C 108.901 -0.777 . . . . 0.95 108.901 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' LYS . . . . . 0.406 ' CE ' ' HA ' ' A' ' 22' ' ' LYS . 0.2 OUTLIER -139.05 15.75 2.64 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.605 -0.684 . . . . 0.79 110.434 179.284 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -92.15 66.04 4.81 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.199 -0.938 . . . . 0.93 108.567 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.596 ' HB2' ' HA ' ' A' ' 12' ' ' PHE . 2.9 p-10 . . . . . 0 N--CA 1.494 1.735 0 O-C-N 121.652 -0.655 . . . . 1.45 109.673 -179.049 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.5 mm100 . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.457 -0.571 . . . . 1.0 109.457 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -87.48 86.33 1.52 Allowed Glycine 0 N--CA 1.497 2.717 0 N-CA-C 109.778 -1.329 . . . . 0.6 109.778 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.488 HD21 ' HB1' ' A' ' 23' ' ' ALA . 5.9 mp -74.71 94.06 2.66 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.748 -0.854 . . . . 0.61 109.573 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.4 -116.72 3.49 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.561 -1.416 . . . . 0.42 109.561 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 50.5 t -86.04 -64.31 1.17 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.634 -0.921 . . . . 0.68 109.468 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -78.63 -40.9 32.95 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.638 -0.664 . . . . 0.79 110.016 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.461 ' HB3' ' HA ' ' A' ' 3' ' ' LEU . 1.0 OUTLIER -65.44 -22.37 66.75 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.47 -0.768 . . . . 0.48 110.383 -179.802 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -55.93 -55.8 28.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.161 -0.962 . . . . 1.68 108.575 179.182 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tp -66.53 -40.58 89.2 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.716 -0.615 . . . . 0.55 109.354 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.429 ' HB2' ' HA ' ' A' ' 7' ' ' GLU . 34.7 mm-40 -62.98 -31.56 72.71 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.72 -0.612 . . . . 0.59 110.332 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.442 ' HA3' HD21 ' A' ' 3' ' ' LEU . . . -63.33 -34.58 90.33 Favored Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.606 -1.398 . . . . 0.26 109.606 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -77.09 -38.33 52.57 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 108.328 -0.99 . . . . 0.39 108.328 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.6 -44.07 83.14 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.986 -0.446 . . . . 0.36 109.94 179.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 10' ' ' GLN . 11.6 p -73.83 -38.88 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.567 -0.708 . . . . 0.46 110.077 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.516 ' HB1' ' HA ' ' A' ' 20' ' ' ALA . . . -69.37 -47.72 63.43 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.421 -0.799 . . . . 0.26 110.03 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.2 p -63.5 -22.51 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.382 -0.824 . . . . 0.36 110.326 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.3 -46.12 9.47 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.415 -0.803 . . . . 1.11 110.389 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mtt -88.66 -53.26 4.72 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.5 -0.75 . . . . 2.23 110.224 -179.343 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 174.78 120.84 0.61 Allowed Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.479 -1.448 . . . . 0.31 109.479 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.516 ' HA ' ' HB1' ' A' ' 15' ' ' ALA . . . -65.1 103.4 0.75 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.742 -0.858 . . . . 0.53 109.83 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 24.1 p -103.64 -63.17 1.21 Allowed 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.547 -0.721 . . . . 0.61 109.618 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -145.67 31.59 1.06 Allowed 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.575 -0.703 . . . . 1.42 110.246 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.488 ' HB1' HD21 ' A' ' 3' ' ' LEU . . . -160.39 87.68 0.77 Allowed 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.154 -0.966 . . . . 0.64 109.916 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.878 0 O-C-N 121.372 -0.83 . . . . 1.04 109.701 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.567 -0.531 . . . . 2.21 109.567 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -114.35 57.6 0.46 Allowed Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.755 -1.338 . . . . 1.06 109.755 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LEU . . . . . 0.578 ' HA ' ' HB2' ' A' ' 7' ' ' GLU . 3.8 tp -141.88 89.23 2.17 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.624 -0.927 . . . . 1.04 109.671 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -99.2 -130.26 6.86 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.531 -1.427 . . . . 0.72 109.531 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.9 t -85.65 -40.62 15.99 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.723 -0.869 . . . . 1.22 110.123 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.484 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.6 t70 -79.43 -42.25 25.83 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.434 -0.791 . . . . 1.82 110.325 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.578 ' HB2' ' HA ' ' A' ' 3' ' ' LEU . 1.3 mp0 -63.64 -45.46 90.1 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.403 -0.81 . . . . 0.79 109.652 -179.422 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.437 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 17.1 ptt? -61.59 -40.82 96.16 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 108.42 -0.956 . . . . 0.95 108.42 178.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.437 ' N ' ' HG3' ' A' ' 8' ' ' MET . 9.8 tp -62.17 -45.63 92.55 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.986 -0.746 . . . . 0.65 108.986 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.484 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 40.6 mm-40 -61.85 -31.98 72.28 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.653 -0.655 . . . . 0.6 109.411 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.94 -30.1 76.38 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.428 -1.469 . . . . 0.51 109.428 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.412 ' HA ' ' O ' ' A' ' 21' ' ' THR . 3.9 m-85 -82.29 -36.95 26.52 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.56 -0.964 . . . . 0.71 108.501 179.078 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.4 -42.92 99.8 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 109.063 -0.717 . . . . 0.46 109.063 178.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 10' ' ' GLN . 14.8 p -76.27 -36.89 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.651 -0.656 . . . . 0.62 109.33 179.223 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.419 ' HB1' ' O ' ' A' ' 20' ' ' ALA . . . -67.48 -50.4 59.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.573 -0.705 . . . . 0.43 109.704 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p -60.52 -33.35 54.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.686 -0.634 . . . . 0.51 109.537 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 6.5 tptp -64.82 -35.17 80.24 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 109.03 -0.729 . . . . 0.93 109.03 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 75.5 mtp -84.58 -47.23 10.76 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.743 -0.598 . . . . 2.13 109.428 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -168.53 -94.53 0.1 OUTLIER Glycine 0 N--CA 1.497 2.718 0 N-CA-C 110.282 -1.127 . . . . 0.43 110.282 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.419 ' O ' ' HB1' ' A' ' 15' ' ' ALA . . . -75.63 132.85 40.89 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.685 -0.891 . . . . 0.67 110.5 -179.302 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.412 ' O ' ' HA ' ' A' ' 12' ' ' PHE . 12.6 t -71.5 -32.66 68.47 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.594 -0.691 . . . . 0.86 110.269 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.68 -44.84 85.0 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.392 -0.818 . . . . 1.91 109.936 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -168.12 124.44 1.05 Allowed 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 109.473 -0.566 . . . . 1.14 109.473 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.3 t70 . . . . . 0 N--CA 1.495 1.786 0 O-C-N 121.628 -0.67 . . . . 1.17 109.68 -179.883 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 N-CA-C 109.671 -0.492 . . . . 2.47 109.671 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -140.05 91.09 0.19 Allowed Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.555 -1.418 . . . . 0.96 109.555 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.4 tp -60.99 108.06 0.81 Allowed 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.701 -0.882 . . . . 2.11 109.732 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 139.1 -90.57 0.19 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.736 -1.346 . . . . 0.69 109.736 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 45.4 t -85.69 -41.04 15.5 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.81 -0.818 . . . . 0.88 110.43 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.455 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 11.0 m-20 -73.43 -46.43 48.56 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.439 -0.788 . . . . 0.98 110.117 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.73 -44.5 89.97 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.575 -0.703 . . . . 0.88 110.1 -179.484 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' MET . . . . . 0.427 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 14.8 ptt? -61.87 -40.04 93.99 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.365 -0.835 . . . . 1.33 108.878 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.43 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 11.3 tp -60.7 -42.05 96.42 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.008 -0.738 . . . . 0.85 109.008 179.031 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLN . . . . . 0.455 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 40.8 mm-40 -64.32 -31.99 73.42 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.688 -0.633 . . . . 0.76 109.35 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.46 82.92 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.422 -1.471 . . . . 0.62 109.422 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.43 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.6 m-85 -80.96 -37.16 29.87 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.191 -1.041 . . . . 0.81 108.191 178.918 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.04 -46.79 76.6 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 109.599 -0.519 . . . . 0.59 109.599 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.419 HG12 ' O ' ' A' ' 10' ' ' GLN . 14.4 p -65.18 -37.26 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.613 -0.68 . . . . 0.61 109.89 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ALA . . . . . 0.436 ' HA ' ' HB2' ' A' ' 24' ' ' ASP . . . -66.05 -49.59 67.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.733 . . . . 0.5 110.098 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.17 -32.88 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.673 -0.642 . . . . 0.65 110.174 -179.525 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.29 -40.55 67.49 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.466 -0.772 . . . . 1.11 110.0 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 32.5 mmm -80.23 -40.35 27.25 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.58 -0.7 . . . . 1.35 109.777 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 99.79 48.26 1.66 Allowed Glycine 0 N--CA 1.496 2.685 0 N-CA-C 109.535 -1.426 . . . . 0.82 109.535 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.442 ' HB1' ' HB3' ' A' ' 23' ' ' ALA . . . -149.45 120.95 7.95 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.602 -0.94 . . . . 0.9 109.724 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 20.3 p -82.52 -58.87 2.73 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.586 -0.696 . . . . 2.02 109.546 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.69 63.77 8.24 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.536 -0.727 . . . . 2.5 109.307 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ALA . . . . . 0.442 ' HB3' ' HB1' ' A' ' 20' ' ' ALA . . . -179.85 -81.9 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.647 -0.658 . . . . 1.2 109.575 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . 0.436 ' HB2' ' HA ' ' A' ' 15' ' ' ALA . 9.7 m-20 . . . . . 0 N--CA 1.496 1.836 0 O-C-N 121.411 -0.806 . . . . 1.6 109.612 179.894 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.4 tp . . . . . 0 N--CA 1.492 1.647 0 N-CA-C 108.9 -0.778 . . . . 0.58999999999999997 108.9 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 45.3 mm-40 -65.01 -31.74 73.12 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 109.234 -0.654 . . . . 0.71999999999999997 109.234 179.054 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -31.88 79.94 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.476 -1.45 . . . . 0.40000000000000002 109.476 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -80.18 -37.95 32.26 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.552 -0.969 . . . . 0.5 108.401 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.86 -42.71 99.86 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 109.287 -0.634 . . . . 0.44 109.287 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.5 p -74.32 -37.13 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.686 . . . . 0.42999999999999999 109.662 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -65.69 -51.14 61.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.523 -0.736 . . . . 0.32000000000000001 109.784 179.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.494 1.748 0 O-C-N 121.75 -0.593 . . . . 0.5 109.749 -179.855 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.445 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 7.8 tp . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 108.882 -0.784 . . . . 0.66000000000000003 108.882 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.4 ' O ' HG12 ' A' ' 14' ' ' VAL . 50.9 mm-40 -63.1 -31.56 72.72 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.7 -0.625 . . . . 0.71999999999999997 109.451 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.57 -30.57 75.05 Favored Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.595 -1.402 . . . . 0.5 109.595 179.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.445 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.67 -38.11 26.4 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.281 -1.007 . . . . 0.64000000000000001 108.281 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.53 -48.11 73.61 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.519 -0.549 . . . . 0.52000000000000002 109.519 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 10' ' ' GLN . 12.1 p -64.21 -36.67 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.61 -0.681 . . . . 0.45000000000000001 109.742 179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.45 -48.9 63.33 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.40999999999999998 110.165 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 N--CA 1.494 1.761 0 O-C-N 121.686 -0.634 . . . . 0.60999999999999999 110.338 -179.327 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 12.1 tp . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.62 -0.511 . . . . 0.76000000000000001 109.62 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.405 ' O ' HG13 ' A' ' 14' ' ' VAL . 43.6 mm-40 -65.12 -30.37 71.3 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.562 -0.711 . . . . 0.88 110.022 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.81 -27.07 71.6 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.787 -1.325 . . . . 0.53000000000000003 109.787 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.536 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -80.16 -36.35 35.22 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.483 -1.01 . . . . 0.66000000000000003 108.462 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -69.86 -48.43 58.88 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.419 -0.586 . . . . 0.54000000000000004 109.419 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 15' ' ' ALA . 28.3 m -62.51 -37.06 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.622 -0.673 . . . . 0.62 109.7 179.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . 0.41 ' N ' HG23 ' A' ' 14' ' ' VAL . . . -74.15 -49.45 23.65 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.735 -0.603 . . . . 0.34000000000000002 110.21 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.8 p . . . . . 0 N--CA 1.496 1.856 0 O-C-N 121.624 -0.673 . . . . 0.54000000000000004 109.951 -179.599 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.518 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.6 tp . . . . . 0 N--CA 1.492 1.635 0 N-CA-C 109.347 -0.612 . . . . 1.27 109.347 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 43.6 mm-40 -62.48 -30.94 71.63 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.673 -0.642 . . . . 0.93999999999999995 109.785 179.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -31.01 75.47 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.583 -1.407 . . . . 1.02 109.583 179.355 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.518 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.37 -39.1 25.56 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 108.199 -1.037 . . . . 1.6399999999999999 108.199 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.79 -43.56 95.98 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 109.551 -0.537 . . . . 0.81999999999999995 109.551 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.5 -37.36 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.582 -0.699 . . . . 0.72999999999999998 109.738 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.01 -48.91 61.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.51 -0.744 . . . . 1.1499999999999999 109.977 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.0 p . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.766 -0.584 . . . . 1.4199999999999999 110.286 -179.563 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.464 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 9.4 tp . . . . . 0 N--CA 1.491 1.624 0 N-CA-C 109.025 -0.731 . . . . 0.66000000000000003 109.025 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 39.5 mm-40 -64.54 -30.22 71.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.686 -0.634 . . . . 0.81000000000000005 109.467 179.204 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.43 -31.52 74.14 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.805 -1.318 . . . . 0.40999999999999998 109.805 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.464 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -77.19 -37.49 53.49 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.488 -1.007 . . . . 0.44 108.619 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.6 -45.62 86.15 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.28 -0.637 . . . . 0.44 109.28 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.3 p -74.72 -35.29 36.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.58 -0.7 . . . . 0.46999999999999997 109.639 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.78 -46.1 66.54 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.575 -0.703 . . . . 0.45000000000000001 110.561 -179.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.494 1.747 0 O-C-N 121.517 -0.739 . . . . 0.62 109.618 -179.709 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.45 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.3 tp . . . . . 0 N--CA 1.492 1.648 0 N-CA-C 109.165 -0.68 . . . . 0.60999999999999999 109.165 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 42.1 mm-40 -62.62 -31.02 71.79 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.732 -0.605 . . . . 0.60999999999999999 109.658 179.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.73 -31.91 76.95 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.478 -1.449 . . . . 0.42999999999999999 109.478 179.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.45 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.8 m-85 -81.12 -38.59 26.97 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 108.228 -1.027 . . . . 0.57999999999999996 108.228 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.27 -46.89 78.65 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.416 -0.587 . . . . 0.39000000000000001 109.416 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -66.49 -36.48 77.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.587 -0.695 . . . . 0.42999999999999999 109.711 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.73 -49.24 55.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.551 -0.718 . . . . 0.41999999999999998 109.979 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 0.47999999999999998 109.875 -179.794 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tp . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 108.629 -0.878 . . . . 0.62 108.629 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 47.0 mm-40 -65.72 -31.22 72.1 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.39 -0.596 . . . . 0.56000000000000005 109.39 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.88 -31.98 79.73 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 109.453 -1.459 . . . . 0.34000000000000002 109.453 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -80.01 -38.43 32.11 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.257 -1.016 . . . . 0.42999999999999999 108.257 178.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.97 -43.8 94.66 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 109.422 -0.585 . . . . 0.38 109.422 179.091 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.6 p -72.16 -37.8 60.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.491 -0.756 . . . . 0.45000000000000001 109.521 179.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.76 -49.19 60.77 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.465 -0.772 . . . . 0.31 109.998 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 N--CA 1.494 1.76 0 O-C-N 121.737 -0.602 . . . . 0.39000000000000001 110.008 -179.655 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tp . . . . . 0 N--CA 1.493 1.678 0 N-CA-C 109.354 -0.61 . . . . 0.55000000000000004 109.354 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.424 ' O ' HG12 ' A' ' 14' ' ' VAL . 34.7 mm-40 -62.98 -31.56 72.71 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.72 -0.612 . . . . 0.58999999999999997 110.332 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -63.33 -34.58 90.33 Favored Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.606 -1.398 . . . . 0.26000000000000001 109.606 179.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -77.09 -38.33 52.57 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 108.328 -0.99 . . . . 0.39000000000000001 108.328 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.6 -44.07 83.14 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.986 -0.446 . . . . 0.35999999999999999 109.94 179.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 10' ' ' GLN . 11.6 p -73.83 -38.88 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.567 -0.708 . . . . 0.46000000000000002 110.077 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.37 -47.72 63.43 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.421 -0.799 . . . . 0.26000000000000001 110.03 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.2 p . . . . . 0 N--CA 1.494 1.771 0 O-C-N 121.382 -0.824 . . . . 0.35999999999999999 110.326 -179.701 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.8 tp . . . . . 0 N--CA 1.491 1.599 0 N-CA-C 108.986 -0.746 . . . . 0.65000000000000002 108.986 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.4 ' O ' HG12 ' A' ' 14' ' ' VAL . 40.6 mm-40 -61.85 -31.98 72.28 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.653 -0.655 . . . . 0.59999999999999998 109.411 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.94 -30.1 76.38 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.428 -1.469 . . . . 0.51000000000000001 109.428 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -82.29 -36.95 26.52 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.56 -0.964 . . . . 0.70999999999999996 108.501 179.078 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.4 -42.92 99.8 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 109.063 -0.717 . . . . 0.46000000000000002 109.063 178.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 10' ' ' GLN . 14.8 p -76.27 -36.89 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.651 -0.656 . . . . 0.62 109.33 179.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -67.48 -50.4 59.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.573 -0.705 . . . . 0.42999999999999999 109.704 179.716 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.496 1.844 0 O-C-N 121.686 -0.634 . . . . 0.51000000000000001 109.537 179.917 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.43 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 11.3 tp . . . . . 0 N--CA 1.49 1.547 0 N-CA-C 109.008 -0.738 . . . . 0.84999999999999998 109.008 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLN . . . . . 0.419 ' O ' HG12 ' A' ' 14' ' ' VAL . 40.8 mm-40 -64.32 -31.99 73.42 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.688 -0.633 . . . . 0.76000000000000001 109.35 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.46 82.92 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.422 -1.471 . . . . 0.62 109.422 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' PHE . . . . . 0.43 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.6 m-85 -80.96 -37.16 29.87 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.191 -1.041 . . . . 0.81000000000000005 108.191 178.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.04 -46.79 76.6 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 109.599 -0.519 . . . . 0.58999999999999997 109.599 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.419 HG12 ' O ' ' A' ' 10' ' ' GLN . 14.4 p -65.18 -37.26 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.613 -0.68 . . . . 0.60999999999999999 109.89 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -66.05 -49.59 67.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.733 . . . . 0.5 110.098 -179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.673 -0.642 . . . . 0.65000000000000002 110.174 -179.525 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.733 0 CA-C-O 121.418 0.628 . . . . 2.1299999999999999 110.001 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.94 -81.86 0.04 OUTLIER Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.536 -1.426 . . . . 0.84999999999999998 109.536 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 9.0 tp -150.89 56.31 0.9 Allowed 'General case' 0 N--CA 1.496 1.874 0 O-C-N 121.687 -0.89 . . . . 1.1499999999999999 109.674 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -85.55 -130.68 2.45 Favored Glycine 0 N--CA 1.495 2.609 0 N-CA-C 109.943 -1.263 . . . . 0.55000000000000004 109.943 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 33.2 t -85.4 -45.32 11.99 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.671 -0.899 . . . . 0.93000000000000005 110.179 -179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.494 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.4 t70 -76.08 -40.48 53.04 Favored 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.441 -0.787 . . . . 0.93000000000000005 110.033 -179.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.4 mp0 -63.89 -47.13 81.85 Favored 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.543 -0.723 . . . . 0.66000000000000003 109.637 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.402 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 21.7 ptt? -62.17 -39.72 93.62 Favored 'General case' 0 N--CA 1.495 1.808 0 N-CA-C 108.553 -0.906 . . . . 0.76000000000000001 108.553 178.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.402 ' N ' ' HG3' ' A' ' 8' ' ' MET . 9.4 tp -60.64 -42.62 97.3 Favored 'General case' 0 N--CA 1.492 1.647 0 N-CA-C 108.9 -0.778 . . . . 0.58999999999999997 108.9 178.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.494 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 45.3 mm-40 -65.01 -31.74 73.12 Favored 'General case' 0 N--CA 1.495 1.817 0 N-CA-C 109.234 -0.654 . . . . 0.71999999999999997 109.234 179.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.57 -31.88 79.94 Favored Glycine 0 N--CA 1.495 2.613 0 N-CA-C 109.476 -1.45 . . . . 0.40000000000000002 109.476 179.331 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -80.18 -37.95 32.26 Favored 'General case' 0 N--CA 1.497 1.9 0 O-C-N 121.552 -0.969 . . . . 0.5 108.401 179.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.86 -42.71 99.86 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 109.287 -0.634 . . . . 0.44 109.287 179.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.5 p -74.32 -37.13 44.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.603 -0.686 . . . . 0.42999999999999999 109.662 179.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.581 ' HB2' ' HA ' ' A' ' 23' ' ' ALA . . . -65.69 -51.14 61.71 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.523 -0.736 . . . . 0.32000000000000001 109.784 179.809 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p -64.24 -32.7 58.52 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.748 0 O-C-N 121.75 -0.593 . . . . 0.5 109.749 -179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . 0.41 ' HA ' ' HD2' ' A' ' 17' ' ' LYS . 7.2 tptp -72.25 -40.07 67.97 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.498 -0.751 . . . . 1.04 109.564 179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mmt -77.2 -50.61 12.55 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.613 -0.68 . . . . 2.1800000000000002 109.643 179.947 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 91.28 66.82 1.16 Allowed Glycine 0 N--CA 1.495 2.626 0 N-CA-C 109.671 -1.372 . . . . 0.87 109.671 179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.505 ' HB3' ' CG ' ' A' ' 24' ' ' ASP . . . -140.68 -61.65 0.5 Allowed 'General case' 0 N--CA 1.496 1.857 0 O-C-N 121.651 -0.911 . . . . 0.92000000000000004 109.831 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.702 HG23 ' H ' ' A' ' 23' ' ' ALA . 14.7 t -145.64 -158.95 0.95 Allowed 'General case' 0 N--CA 1.498 1.935 0 O-C-N 121.543 -0.723 . . . . 0.65000000000000002 109.945 -179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 11.4 pttm -70.42 -29.92 66.65 Favored 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.237 -0.914 . . . . 2.1699999999999999 110.654 -179.487 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.702 ' H ' HG23 ' A' ' 21' ' ' THR . . . -142.7 121.38 12.59 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.498 -0.751 . . . . 1.04 109.712 -179.819 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.521 ' OD1' HG22 ' A' ' 21' ' ' THR . 29.3 m-20 . . . . . 0 N--CA 1.497 1.907 0 O-C-N 121.576 -0.702 . . . . 1.5700000000000001 109.675 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 11.5 mt-30 . . . . . 0 N--CA 1.492 1.637 0 N-CA-C 109.574 -0.528 . . . . 0.96999999999999997 109.574 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -114.71 -78.68 0.8 Allowed Glycine 0 N--CA 1.496 2.662 0 N-CA-C 109.433 -1.467 . . . . 0.93999999999999995 109.433 179.758 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -153.36 126.84 8.67 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.738 -0.86 . . . . 1.6699999999999999 109.418 179.72 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.07 -132.48 1.71 Allowed Glycine 0 N--CA 1.495 2.596 0 N-CA-C 109.834 -1.306 . . . . 0.62 109.834 -179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 29.4 t -85.8 -46.17 10.91 Favored 'General case' 0 N--CA 1.497 1.888 0 O-C-N 121.698 -0.883 . . . . 1.1299999999999999 110.063 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.47 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.3 t70 -81.78 -37.88 26.46 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.516 -0.74 . . . . 1.0 110.238 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -64.03 -44.04 93.77 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.399 -0.813 . . . . 0.92000000000000004 109.641 -179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.426 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 25.1 ptt? -62.98 -40.04 96.55 Favored 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 108.475 -0.935 . . . . 1.0800000000000001 108.475 178.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.445 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 7.8 tp -60.97 -42.88 99.2 Favored 'General case' 0 N--CA 1.492 1.642 0 N-CA-C 108.882 -0.784 . . . . 0.66000000000000003 108.882 178.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.47 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 50.9 mm-40 -63.1 -31.56 72.72 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.7 -0.625 . . . . 0.71999999999999997 109.451 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.57 -30.57 75.05 Favored Glycine 0 N--CA 1.495 2.622 0 N-CA-C 109.595 -1.402 . . . . 0.5 109.595 179.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.445 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.67 -38.11 26.4 Favored 'General case' 0 N--CA 1.497 1.924 0 N-CA-C 108.281 -1.007 . . . . 0.64000000000000001 108.281 179.025 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.53 -48.11 73.61 Favored 'General case' 0 N--CA 1.493 1.707 0 N-CA-C 109.519 -0.549 . . . . 0.52000000000000002 109.519 179.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 10' ' ' GLN . 12.1 p -64.21 -36.67 77.75 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.966 0 O-C-N 121.61 -0.681 . . . . 0.45000000000000001 109.742 179.703 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.444 ' HB1' ' HA ' ' A' ' 21' ' ' THR . . . -68.45 -48.9 63.33 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.617 -0.677 . . . . 0.40999999999999998 110.165 -179.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.7 p -70.87 -32.83 50.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.686 -0.634 . . . . 0.60999999999999999 110.338 -179.327 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.16 -41.38 63.96 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.471 -0.768 . . . . 1.0600000000000001 109.991 -179.988 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 42.3 mmm -81.85 -35.06 29.77 Favored 'General case' 0 N--CA 1.498 1.932 0 O-C-N 121.556 -0.715 . . . . 1.4099999999999999 109.997 -179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 98.97 44.02 2.5 Favored Glycine 0 N--CA 1.496 2.7 0 N-CA-C 109.549 -1.42 . . . . 0.64000000000000001 109.549 -179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -158.42 105.42 1.88 Allowed 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.731 -0.864 . . . . 0.84999999999999998 109.472 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.444 ' HA ' ' HB1' ' A' ' 15' ' ' ALA . 60.5 m -77.61 -39.45 45.39 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.561 -0.712 . . . . 1.3600000000000001 109.975 -179.668 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.57 -46.48 54.16 Favored 'General case' 0 N--CA 1.498 1.952 0 O-C-N 121.46 -0.775 . . . . 2.1000000000000001 109.796 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -77.27 -77.99 0.14 Allowed 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.748 -0.595 . . . . 0.84999999999999998 109.687 -179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.417 ' HB2' ' HA ' ' A' ' 15' ' ' ALA . 8.3 m-20 . . . . . 0 N--CA 1.496 1.842 0 O-C-N 121.396 -0.815 . . . . 1.1299999999999999 109.581 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.655 0 CA-C-O 121.112 0.482 . . . . 1.53 109.724 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -87.19 74.9 2.23 Favored Glycine 0 N--CA 1.495 2.599 0 N-CA-C 109.482 -1.447 . . . . 0.84999999999999998 109.482 179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.1 pp -53.95 141.75 26.87 Favored 'General case' 0 N--CA 1.499 2.014 0 O-C-N 121.75 -0.853 . . . . 1.27 110.094 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 91.36 -63.93 2.64 Favored Glycine 0 N--CA 1.495 2.617 0 N-CA-C 109.536 -1.426 . . . . 0.52000000000000002 109.536 -179.663 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 42.4 t -71.86 -45.22 62.12 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.926 -0.75 . . . . 0.90000000000000002 110.179 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.415 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 2.1 m-20 -70.9 -38.87 73.01 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.407 -0.808 . . . . 1.28 109.756 179.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -65.46 -49.82 67.67 Favored 'General case' 0 N--CA 1.498 1.926 0 O-C-N 121.531 -0.731 . . . . 1.05 109.605 -179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 10.7 ptt? -63.55 -34.78 78.56 Favored 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.527 -0.733 . . . . 1.0700000000000001 109.355 179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.536 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 12.1 tp -60.37 -40.45 90.87 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.86 -0.525 . . . . 0.76000000000000001 109.62 179.724 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.415 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 43.6 mm-40 -65.12 -30.37 71.3 Favored 'General case' 0 N--CA 1.497 1.891 0 O-C-N 121.562 -0.711 . . . . 0.88 110.022 179.719 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -64.81 -27.07 71.6 Favored Glycine 0 N--CA 1.496 2.696 0 N-CA-C 109.787 -1.325 . . . . 0.53000000000000003 109.787 179.557 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.536 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -80.16 -36.35 35.22 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.483 -1.01 . . . . 0.66000000000000003 108.462 179.104 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -69.86 -48.43 58.88 Favored 'General case' 0 N--CA 1.493 1.704 0 N-CA-C 109.419 -0.586 . . . . 0.54000000000000004 109.419 179.322 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 15' ' ' ALA . 28.3 m -62.51 -37.06 77.89 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 O-C-N 121.622 -0.673 . . . . 0.62 109.7 179.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.562 ' HB1' ' O ' ' A' ' 20' ' ' ALA . . . -74.15 -49.45 23.65 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.735 -0.603 . . . . 0.34000000000000002 110.21 -179.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.8 p -63.39 -33.81 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 121.624 -0.673 . . . . 0.54000000000000004 109.951 -179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.4 -37.5 71.51 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.521 -0.737 . . . . 1.1699999999999999 109.578 179.513 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 10.2 mmm -76.88 -51.17 11.74 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.52 -0.738 . . . . 1.77 109.53 179.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -166.8 -92.33 0.09 OUTLIER Glycine 0 N--CA 1.496 2.644 0 N-CA-C 110.011 -1.235 . . . . 0.64000000000000001 110.011 179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.562 ' O ' ' HB1' ' A' ' 15' ' ' ALA . . . -82.75 130.18 35.09 Favored 'General case' 0 N--CA 1.497 1.899 0 O-C-N 121.619 -0.93 . . . . 0.79000000000000004 110.081 -179.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.913 HG23 ' HD2' ' A' ' 22' ' ' LYS . 5.0 t -61.71 -22.45 65.36 Favored 'General case' 0 N--CA 1.503 2.184 0 O-C-N 121.741 -0.599 . . . . 0.73999999999999999 110.839 179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.913 ' HD2' HG23 ' A' ' 21' ' ' THR . 0.0 OUTLIER -118.99 33.32 5.7 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.188 -0.945 . . . . 1.0600000000000001 110.162 -179.831 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.485 ' HB3' ' HB3' ' A' ' 20' ' ' ALA . . . -170.25 -93.59 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.975 0 O-C-N 121.22 -0.925 . . . . 1.02 109.865 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.411 ' O ' ' HA ' ' A' ' 15' ' ' ALA . 21.9 t70 . . . . . 0 N--CA 1.495 1.813 0 O-C-N 121.319 -0.863 . . . . 1.0600000000000001 109.51 -179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.666 0 CA-C-O 121.156 0.503 . . . . 2.4300000000000002 109.733 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -119.28 111.62 2.11 Favored Glycine 0 N--CA 1.495 2.6 0 N-CA-C 109.576 -1.41 . . . . 1.1000000000000001 109.576 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 1.2 pp -57.02 147.76 23.29 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.762 -0.846 . . . . 1.45 110.024 -179.965 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 94.02 -62.0 1.89 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.502 -1.439 . . . . 0.93999999999999995 109.502 -179.617 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 44.0 t -70.52 -45.34 65.74 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.846 -0.796 . . . . 1.3 110.245 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.419 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 7.8 m-20 -69.37 -42.41 75.25 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.482 -0.761 . . . . 1.24 109.723 179.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 -65.65 -49.41 68.74 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.72 -0.612 . . . . 1.25 110.18 -179.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 11.1 ptt? -61.43 -36.84 81.48 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.38 -0.825 . . . . 1.6599999999999999 109.517 179.623 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.518 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.6 tp -60.22 -41.09 92.32 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.347 -0.612 . . . . 1.27 109.347 179.495 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.419 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 43.6 mm-40 -62.48 -30.94 71.63 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.673 -0.642 . . . . 0.93999999999999995 109.785 179.517 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.56 -31.01 75.47 Favored Glycine 0 N--CA 1.497 2.739 0 N-CA-C 109.583 -1.407 . . . . 1.02 109.583 179.355 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.518 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.9 m-85 -81.37 -39.1 25.56 Favored 'General case' 0 N--CA 1.496 1.861 0 N-CA-C 108.199 -1.037 . . . . 1.6399999999999999 108.199 179.028 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.79 -43.56 95.98 Favored 'General case' 0 N--CA 1.493 1.699 0 N-CA-C 109.551 -0.537 . . . . 0.81999999999999995 109.551 179.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -70.5 -37.36 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.582 -0.699 . . . . 0.72999999999999998 109.738 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.504 ' HA ' ' HB2' ' A' ' 24' ' ' ASP . . . -69.01 -48.91 61.87 Favored 'General case' 0 N--CA 1.497 1.887 0 O-C-N 121.51 -0.744 . . . . 1.1499999999999999 109.977 179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.0 p -66.56 -30.9 51.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.737 0 O-C-N 121.766 -0.584 . . . . 1.4199999999999999 110.286 -179.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.68 -38.81 28.32 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.447 -0.783 . . . . 1.22 110.436 -179.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 63.0 mmm -65.21 -68.41 0.36 Allowed 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.456 -0.777 . . . . 2.1400000000000001 110.104 -179.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 149.32 59.85 0.01 OUTLIER Glycine 0 N--CA 1.499 2.84 0 N-CA-C 110.093 -1.203 . . . . 1.1799999999999999 110.093 179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -133.07 155.97 48.24 Favored 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.748 -0.854 . . . . 1.3 109.7 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.408 HG23 ' HD2' ' A' ' 22' ' ' LYS . 9.3 t -64.87 -38.19 90.15 Favored 'General case' 0 N--CA 1.5 2.026 0 O-C-N 121.451 -0.781 . . . . 2.5899999999999999 109.972 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.408 ' HD2' HG23 ' A' ' 21' ' ' THR . 0.1 OUTLIER -143.37 -54.4 0.38 Allowed 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.439 -0.788 . . . . 3.3700000000000001 109.717 179.913 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -119.26 129.22 54.81 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.758 -0.589 . . . . 1.8899999999999999 109.572 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.504 ' HB2' ' HA ' ' A' ' 15' ' ' ALA . 8.1 t70 . . . . . 0 N--CA 1.495 1.777 0 O-C-N 121.606 -0.684 . . . . 1.47 109.565 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.667 0 N-CA-C 109.547 -0.538 . . . . 2.8199999999999998 109.547 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 83.62 -95.53 1.88 Allowed Glycine 0 N--CA 1.495 2.606 0 N-CA-C 110.016 -1.234 . . . . 1.1200000000000001 110.016 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -77.72 96.71 4.95 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 121.704 -0.88 . . . . 0.96999999999999997 109.994 -179.618 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 140.13 -100.08 0.27 Allowed Glycine 0 N--CA 1.495 2.606 0 N-CA-C 110.191 -1.164 . . . . 0.45000000000000001 110.191 179.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' O ' ' HG2' ' A' ' 8' ' ' MET . 33.1 t -61.74 -40.74 96.16 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.912 -0.757 . . . . 0.73999999999999999 110.847 -179.223 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.409 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.4 m-20 -79.9 -42.77 23.49 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.338 -0.851 . . . . 0.88 110.105 -179.638 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.1 tm-20 -64.99 -44.66 88.56 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.465 -0.772 . . . . 0.66000000000000003 110.148 -179.616 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.435 ' HA ' ' CE ' ' A' ' 22' ' ' LYS . 17.2 ptt? -56.89 -41.68 78.49 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.327 -0.858 . . . . 1.02 109.188 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.464 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 9.4 tp -60.79 -43.77 97.68 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.025 -0.731 . . . . 0.66000000000000003 109.025 179.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.409 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 39.5 mm-40 -64.54 -30.22 71.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 121.686 -0.634 . . . . 0.81000000000000005 109.467 179.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -68.43 -31.52 74.14 Favored Glycine 0 N--CA 1.494 2.565 0 N-CA-C 109.805 -1.318 . . . . 0.40999999999999998 109.805 179.606 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.464 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 4.2 m-85 -77.19 -37.49 53.49 Favored 'General case' 0 N--CA 1.498 1.93 0 O-C-N 121.488 -1.007 . . . . 0.44 108.619 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -64.6 -45.62 86.15 Favored 'General case' 0 N--CA 1.495 1.785 0 N-CA-C 109.28 -0.637 . . . . 0.44 109.28 179.239 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 14.3 p -74.72 -35.29 36.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 O-C-N 121.58 -0.7 . . . . 0.46999999999999997 109.639 179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.455 ' HB1' ' C ' ' A' ' 20' ' ' ALA . . . -69.78 -46.1 66.54 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.575 -0.703 . . . . 0.45000000000000001 110.561 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p -62.81 -31.76 53.44 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.517 -0.739 . . . . 0.62 109.618 -179.709 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -81.83 -37.55 26.87 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.62 -0.675 . . . . 1.3700000000000001 109.914 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 34.6 mmm -86.97 -66.47 0.9 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.403 -0.81 . . . . 1.79 110.074 -179.584 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 148.76 70.14 0.01 OUTLIER Glycine 0 N--CA 1.498 2.784 0 N-CA-C 110.259 -1.136 . . . . 0.55000000000000004 110.259 179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.455 ' C ' ' HB1' ' A' ' 15' ' ' ALA . . . -166.64 -159.87 0.38 Allowed 'General case' 0 N--CA 1.5 2.054 0 O-C-N 121.581 -0.952 . . . . 0.40999999999999998 109.657 179.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 26.5 p -108.21 -73.56 0.68 Allowed 'General case' 0 N--CA 1.499 1.986 0 O-C-N 121.257 -0.902 . . . . 0.75 109.471 179.921 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.435 ' CE ' ' HA ' ' A' ' 8' ' ' MET . 0.0 OUTLIER -112.87 -27.33 8.15 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.523 -0.736 . . . . 0.62 110.132 179.79 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -138.79 130.52 27.66 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.443 -0.785 . . . . 0.70999999999999996 109.422 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 . . . . . 0 N--CA 1.495 1.805 0 O-C-N 121.586 -0.696 . . . . 1.21 109.53 -179.878 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 . . . . . 0 N--CA 1.492 1.628 0 CA-C-O 121.252 0.549 . . . . 1.1899999999999999 109.536 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -109.12 97.04 1.03 Allowed Glycine 0 N--CA 1.496 2.646 0 N-CA-C 109.446 -1.461 . . . . 0.5 109.446 179.934 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 11.0 mt -57.96 107.01 0.42 Allowed 'General case' 0 N--CA 1.498 1.957 0 O-C-N 121.743 -0.857 . . . . 1.24 109.818 -179.741 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 141.47 -98.78 0.23 Allowed Glycine 0 N--CA 1.494 2.559 0 N-CA-C 109.9 -1.28 . . . . 0.51000000000000001 109.9 -179.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 49.9 t -83.51 -38.97 21.06 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.811 -0.817 . . . . 0.88 110.453 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.474 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 28.2 t70 -71.76 -47.4 53.89 Favored 'General case' 0 N--CA 1.495 1.823 0 O-C-N 121.378 -0.826 . . . . 0.79000000000000004 109.817 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -64.51 -45.8 85.71 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.593 -0.692 . . . . 0.48999999999999999 110.231 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.407 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 11.8 ptt? -61.96 -39.79 93.37 Favored 'General case' 0 N--CA 1.498 1.97 0 O-C-N 121.307 -0.871 . . . . 0.97999999999999998 109.137 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.45 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 10.3 tp -60.83 -42.25 97.36 Favored 'General case' 0 N--CA 1.492 1.648 0 N-CA-C 109.165 -0.68 . . . . 0.60999999999999999 109.165 179.173 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.474 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 42.1 mm-40 -62.62 -31.02 71.79 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.732 -0.605 . . . . 0.60999999999999999 109.658 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -67.73 -31.91 76.95 Favored Glycine 0 N--CA 1.497 2.707 0 N-CA-C 109.478 -1.449 . . . . 0.42999999999999999 109.478 179.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.45 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.8 m-85 -81.12 -38.59 26.97 Favored 'General case' 0 N--CA 1.497 1.921 0 N-CA-C 108.228 -1.027 . . . . 0.57999999999999996 108.228 179.012 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -65.27 -46.89 78.65 Favored 'General case' 0 N--CA 1.493 1.698 0 N-CA-C 109.416 -0.587 . . . . 0.39000000000000001 109.416 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -66.49 -36.48 77.42 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.878 0 O-C-N 121.587 -0.695 . . . . 0.42999999999999999 109.711 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -69.73 -49.24 55.12 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.551 -0.718 . . . . 0.41999999999999998 109.979 -179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 p -65.47 -34.25 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 121.628 -0.67 . . . . 0.47999999999999998 109.875 -179.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -72.83 -40.57 65.64 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.521 -0.737 . . . . 1.1599999999999999 109.52 179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 48.1 mtt -72.2 -50.54 26.74 Favored 'General case' 0 N--CA 1.497 1.885 0 O-C-N 121.632 -0.668 . . . . 2.1099999999999999 109.522 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 112.69 61.73 0.44 Allowed Glycine 0 N--CA 1.496 2.656 0 N-CA-C 109.867 -1.293 . . . . 0.56999999999999995 109.867 179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.66 -54.34 8.35 Favored 'General case' 0 N--CA 1.496 1.837 0 O-C-N 121.708 -0.877 . . . . 0.78000000000000003 109.264 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.411 ' HB ' ' HE2' ' A' ' 22' ' ' LYS . 72.4 p -124.0 -56.02 1.67 Allowed 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.705 -0.622 . . . . 0.95999999999999996 109.465 179.52 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.411 ' HE2' ' HB ' ' A' ' 21' ' ' THR . 0.0 OUTLIER -178.97 -50.04 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.016 0 N-CA-C 109.16 -0.681 . . . . 1.01 109.16 179.846 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -133.28 72.27 1.48 Allowed 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.633 -0.877 . . . . 1.1799999999999999 108.633 179.359 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 . . . . . 0 N--CA 1.495 1.806 0 O-C-N 121.601 -0.687 . . . . 0.85999999999999999 109.678 -179.185 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 N-CA-C 109.248 -0.649 . . . . 1.0800000000000001 109.248 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 73.51 -161.85 54.32 Favored Glycine 0 N--CA 1.498 2.825 0 N-CA-C 109.903 -1.279 . . . . 0.79000000000000004 109.903 -179.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.402 ' C ' ' HB2' ' A' ' 7' ' ' GLU . 0.6 OUTLIER -161.59 143.23 11.45 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.451 -1.029 . . . . 1.4199999999999999 110.037 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 161.94 -117.04 0.75 Allowed Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.019 -1.633 . . . . 0.52000000000000002 109.019 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.417 ' O ' ' HG2' ' A' ' 8' ' ' MET . 40.4 t -85.73 -73.91 0.43 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.642 -0.917 . . . . 0.80000000000000004 108.789 179.222 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -88.22 -21.45 24.52 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.541 -0.724 . . . . 0.91000000000000003 109.584 179.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.402 ' HB2' ' C ' ' A' ' 3' ' ' LEU . 1.2 mp0 -66.17 -36.99 84.56 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.539 -0.725 . . . . 0.66000000000000003 110.113 -179.645 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.423 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 27.1 ptt? -58.78 -43.24 90.38 Favored 'General case' 0 N--CA 1.498 1.94 0 O-C-N 121.41 -0.807 . . . . 0.96999999999999997 109.181 179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.423 ' N ' ' HG3' ' A' ' 8' ' ' MET . 9.2 tp -60.85 -42.16 97.29 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.629 -0.878 . . . . 0.62 108.629 178.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . . . . . . . . . 47.0 mm-40 -65.72 -31.22 72.1 Favored 'General case' 0 N--CA 1.494 1.76 0 N-CA-C 109.39 -0.596 . . . . 0.56000000000000005 109.39 179.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -66.88 -31.98 79.73 Favored Glycine 0 N--CA 1.497 2.704 0 N-CA-C 109.453 -1.459 . . . . 0.34000000000000002 109.453 179.367 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.596 ' HA ' ' HB2' ' A' ' 24' ' ' ASP . 2.9 m-85 -80.01 -38.43 32.11 Favored 'General case' 0 N--CA 1.496 1.832 0 N-CA-C 108.257 -1.016 . . . . 0.42999999999999999 108.257 178.991 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -63.97 -43.8 94.66 Favored 'General case' 0 N--CA 1.494 1.743 0 N-CA-C 109.422 -0.585 . . . . 0.38 109.422 179.091 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.42 HG22 ' SD ' ' A' ' 18' ' ' MET . 11.6 p -72.16 -37.8 60.71 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.859 0 O-C-N 121.491 -0.756 . . . . 0.45000000000000001 109.521 179.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . . . . . . . . . . . -68.76 -49.19 60.77 Favored 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.465 -0.772 . . . . 0.31 109.998 179.881 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 8.5 p -60.91 -34.15 58.42 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.737 -0.602 . . . . 0.39000000000000001 110.008 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -80.0 -37.53 33.98 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.505 -0.747 . . . . 2.4199999999999999 110.335 -179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . 0.42 ' SD ' HG22 ' A' ' 14' ' ' VAL . 48.6 mtp -64.76 -56.84 11.11 Favored 'General case' 0 N--CA 1.499 1.978 0 O-C-N 121.431 -0.793 . . . . 1.98 110.075 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -175.43 87.51 0.08 OUTLIER Glycine 0 N--CA 1.497 2.712 0 N-CA-C 109.546 -1.422 . . . . 0.73999999999999999 109.546 -179.853 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . 178.62 127.81 0.06 Allowed 'General case' 0 N--CA 1.499 1.993 0 O-C-N 121.906 -0.761 . . . . 0.47999999999999998 109.703 -179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 21.2 p -71.21 -64.38 0.92 Allowed 'General case' 0 N--CA 1.499 1.978 0 N-CA-C 108.901 -0.777 . . . . 0.94999999999999996 108.901 179.504 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . 0.406 ' CE ' ' HA ' ' A' ' 22' ' ' LYS . 0.2 OUTLIER -139.05 15.75 2.64 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.605 -0.684 . . . . 0.79000000000000004 110.434 179.284 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -92.15 66.04 4.81 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.199 -0.938 . . . . 0.93000000000000005 108.567 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.596 ' HB2' ' HA ' ' A' ' 12' ' ' PHE . 2.9 p-10 . . . . . 0 N--CA 1.494 1.735 0 O-C-N 121.652 -0.655 . . . . 1.45 109.673 -179.049 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 2.5 mm100 . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.457 -0.571 . . . . 1.0 109.457 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -87.48 86.33 1.52 Allowed Glycine 0 N--CA 1.497 2.717 0 N-CA-C 109.778 -1.329 . . . . 0.59999999999999998 109.778 -179.768 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.488 HD21 ' HB1' ' A' ' 23' ' ' ALA . 5.9 mp -74.71 94.06 2.66 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.748 -0.854 . . . . 0.60999999999999999 109.573 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.4 -116.72 3.49 Favored Glycine 0 N--CA 1.496 2.672 0 N-CA-C 109.561 -1.416 . . . . 0.41999999999999998 109.561 -179.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 50.5 t -86.04 -64.31 1.17 Allowed 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.634 -0.921 . . . . 0.68000000000000005 109.468 179.812 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -78.63 -40.9 32.95 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.638 -0.664 . . . . 0.79000000000000004 110.016 -179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.461 ' HB3' ' HA ' ' A' ' 3' ' ' LEU . 1.0 OUTLIER -65.44 -22.37 66.75 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.47 -0.768 . . . . 0.47999999999999998 110.383 -179.802 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -55.93 -55.8 28.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.161 -0.962 . . . . 1.6799999999999999 108.575 179.182 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 9.2 tp -66.53 -40.58 89.2 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.716 -0.615 . . . . 0.55000000000000004 109.354 179.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.429 ' HB2' ' HA ' ' A' ' 7' ' ' GLU . 34.7 mm-40 -62.98 -31.56 72.71 Favored 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.72 -0.612 . . . . 0.58999999999999997 110.332 -179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.442 ' HA3' HD21 ' A' ' 3' ' ' LEU . . . -63.33 -34.58 90.33 Favored Glycine 0 N--CA 1.495 2.625 0 N-CA-C 109.606 -1.398 . . . . 0.26000000000000001 109.606 179.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -77.09 -38.33 52.57 Favored 'General case' 0 N--CA 1.497 1.892 0 N-CA-C 108.328 -0.99 . . . . 0.39000000000000001 108.328 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.6 -44.07 83.14 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.986 -0.446 . . . . 0.35999999999999999 109.94 179.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.424 HG12 ' O ' ' A' ' 10' ' ' GLN . 11.6 p -73.83 -38.88 51.45 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.567 -0.708 . . . . 0.46000000000000002 110.077 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.516 ' HB1' ' HA ' ' A' ' 20' ' ' ALA . . . -69.37 -47.72 63.43 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.421 -0.799 . . . . 0.26000000000000001 110.03 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.2 p -63.5 -22.51 31.04 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.382 -0.824 . . . . 0.35999999999999999 110.326 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -88.3 -46.12 9.47 Favored 'General case' 0 N--CA 1.495 1.811 0 O-C-N 121.415 -0.803 . . . . 1.1100000000000001 110.389 -179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 4.3 mtt -88.66 -53.26 4.72 Favored 'General case' 0 N--CA 1.499 2.0 0 O-C-N 121.5 -0.75 . . . . 2.23 110.224 -179.343 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 174.78 120.84 0.61 Allowed Glycine 0 N--CA 1.497 2.716 0 N-CA-C 109.479 -1.448 . . . . 0.31 109.479 -179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.516 ' HA ' ' HB1' ' A' ' 15' ' ' ALA . . . -65.1 103.4 0.75 Allowed 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.742 -0.858 . . . . 0.53000000000000003 109.83 -179.686 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 24.1 p -103.64 -63.17 1.21 Allowed 'General case' 0 N--CA 1.497 1.919 0 O-C-N 121.547 -0.721 . . . . 0.60999999999999999 109.618 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -145.67 31.59 1.06 Allowed 'General case' 0 N--CA 1.498 1.934 0 O-C-N 121.575 -0.703 . . . . 1.4199999999999999 110.246 -179.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.488 ' HB1' HD21 ' A' ' 3' ' ' LEU . . . -160.39 87.68 0.77 Allowed 'General case' 0 N--CA 1.497 1.893 0 O-C-N 121.154 -0.966 . . . . 0.64000000000000001 109.916 179.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.497 1.878 0 O-C-N 121.372 -0.83 . . . . 1.04 109.701 179.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.601 0 N-CA-C 109.567 -0.531 . . . . 2.21 109.567 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -114.35 57.6 0.46 Allowed Glycine 0 N--CA 1.497 2.703 0 N-CA-C 109.755 -1.338 . . . . 1.0600000000000001 109.755 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . 0.578 ' HA ' ' HB2' ' A' ' 7' ' ' GLU . 3.8 tp -141.88 89.23 2.17 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.624 -0.927 . . . . 1.04 109.671 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -99.2 -130.26 6.86 Favored Glycine 0 N--CA 1.494 2.527 0 N-CA-C 109.531 -1.427 . . . . 0.71999999999999997 109.531 179.844 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 12.9 t -85.65 -40.62 15.99 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.723 -0.869 . . . . 1.22 110.123 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.484 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 8.6 t70 -79.43 -42.25 25.83 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 121.434 -0.791 . . . . 1.8200000000000001 110.325 -179.579 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.578 ' HB2' ' HA ' ' A' ' 3' ' ' LEU . 1.3 mp0 -63.64 -45.46 90.1 Favored 'General case' 0 N--CA 1.499 1.989 0 O-C-N 121.403 -0.81 . . . . 0.79000000000000004 109.652 -179.422 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.437 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 17.1 ptt? -61.59 -40.82 96.16 Favored 'General case' 0 N--CA 1.495 1.814 0 N-CA-C 108.42 -0.956 . . . . 0.94999999999999996 108.42 178.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.437 ' N ' ' HG3' ' A' ' 8' ' ' MET . 9.8 tp -62.17 -45.63 92.55 Favored 'General case' 0 N--CA 1.491 1.599 0 N-CA-C 108.986 -0.746 . . . . 0.65000000000000002 108.986 178.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.484 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 40.6 mm-40 -61.85 -31.98 72.28 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.653 -0.655 . . . . 0.59999999999999998 109.411 179.301 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.94 -30.1 76.38 Favored Glycine 0 N--CA 1.495 2.575 0 N-CA-C 109.428 -1.469 . . . . 0.51000000000000001 109.428 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.412 ' HA ' ' O ' ' A' ' 21' ' ' THR . 3.9 m-85 -82.29 -36.95 26.52 Favored 'General case' 0 N--CA 1.497 1.889 0 O-C-N 121.56 -0.964 . . . . 0.70999999999999996 108.501 179.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -62.4 -42.92 99.8 Favored 'General case' 0 N--CA 1.495 1.81 0 N-CA-C 109.063 -0.717 . . . . 0.46000000000000002 109.063 178.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.4 HG12 ' O ' ' A' ' 10' ' ' GLN . 14.8 p -76.27 -36.89 30.88 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.813 0 O-C-N 121.651 -0.656 . . . . 0.62 109.33 179.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.419 ' HB1' ' O ' ' A' ' 20' ' ' ALA . . . -67.48 -50.4 59.18 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.573 -0.705 . . . . 0.42999999999999999 109.704 179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p -60.52 -33.35 54.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.686 -0.634 . . . . 0.51000000000000001 109.537 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 6.5 tptp -64.82 -35.17 80.24 Favored 'General case' 0 N--CA 1.494 1.73 0 N-CA-C 109.03 -0.729 . . . . 0.93000000000000005 109.03 179.045 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 75.5 mtp -84.58 -47.23 10.76 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.743 -0.598 . . . . 2.1299999999999999 109.428 179.535 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . -168.53 -94.53 0.1 OUTLIER Glycine 0 N--CA 1.497 2.718 0 N-CA-C 110.282 -1.127 . . . . 0.42999999999999999 110.282 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.419 ' O ' ' HB1' ' A' ' 15' ' ' ALA . . . -75.63 132.85 40.89 Favored 'General case' 0 N--CA 1.499 2.003 0 O-C-N 121.685 -0.891 . . . . 0.67000000000000004 110.5 -179.302 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.412 ' O ' ' HA ' ' A' ' 12' ' ' PHE . 12.6 t -71.5 -32.66 68.47 Favored 'General case' 0 N--CA 1.5 2.042 0 O-C-N 121.594 -0.691 . . . . 0.85999999999999999 110.269 179.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -65.68 -44.84 85.0 Favored 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.392 -0.818 . . . . 1.9099999999999999 109.936 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . . . . . . . . . . . -168.12 124.44 1.05 Allowed 'General case' 0 N--CA 1.496 1.869 0 N-CA-C 109.473 -0.566 . . . . 1.1399999999999999 109.473 -179.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 6.3 t70 . . . . . 0 N--CA 1.495 1.786 0 O-C-N 121.628 -0.67 . . . . 1.1699999999999999 109.68 -179.883 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 N-CA-C 109.671 -0.492 . . . . 2.4700000000000002 109.671 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -140.05 91.09 0.19 Allowed Glycine 0 N--CA 1.496 2.69 0 N-CA-C 109.555 -1.418 . . . . 0.95999999999999996 109.555 179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LEU . . . . . . . . . . . . . 2.4 tp -60.99 108.06 0.81 Allowed 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.701 -0.882 . . . . 2.1099999999999999 109.732 -179.796 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 139.1 -90.57 0.19 Allowed Glycine 0 N--CA 1.494 2.501 0 N-CA-C 109.736 -1.346 . . . . 0.68999999999999995 109.736 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 45.4 t -85.69 -41.04 15.5 Favored 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.81 -0.818 . . . . 0.88 110.43 -179.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.455 ' O ' ' HG2' ' A' ' 10' ' ' GLN . 11.0 m-20 -73.43 -46.43 48.56 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.439 -0.788 . . . . 0.97999999999999998 110.117 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -64.73 -44.5 89.97 Favored 'General case' 0 N--CA 1.497 1.884 0 O-C-N 121.575 -0.703 . . . . 0.88 110.1 -179.484 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' MET . . . . . 0.427 ' HG3' ' N ' ' A' ' 9' ' ' LEU . 14.8 ptt? -61.87 -40.04 93.99 Favored 'General case' 0 N--CA 1.498 1.941 0 O-C-N 121.365 -0.835 . . . . 1.3300000000000001 108.878 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.43 ' HA ' ' CD2' ' A' ' 12' ' ' PHE . 11.3 tp -60.7 -42.05 96.42 Favored 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 109.008 -0.738 . . . . 0.84999999999999998 109.008 179.031 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLN . . . . . 0.455 ' HG2' ' O ' ' A' ' 6' ' ' ASP . 40.8 mm-40 -64.32 -31.99 73.42 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.688 -0.633 . . . . 0.76000000000000001 109.35 179.232 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -65.81 -32.46 82.92 Favored Glycine 0 N--CA 1.497 2.729 0 N-CA-C 109.422 -1.471 . . . . 0.62 109.422 179.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.43 ' CD2' ' HA ' ' A' ' 9' ' ' LEU . 2.6 m-85 -80.96 -37.16 29.87 Favored 'General case' 0 N--CA 1.497 1.913 0 N-CA-C 108.191 -1.041 . . . . 0.81000000000000005 108.191 178.918 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ALA . . . . . . . . . . . . . . . -66.04 -46.79 76.6 Favored 'General case' 0 N--CA 1.493 1.675 0 N-CA-C 109.599 -0.519 . . . . 0.58999999999999997 109.599 179.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.419 HG12 ' O ' ' A' ' 10' ' ' GLN . 14.4 p -65.18 -37.26 79.75 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.613 -0.68 . . . . 0.60999999999999999 109.89 179.81 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ALA . . . . . 0.436 ' HA ' ' HB2' ' A' ' 24' ' ' ASP . . . -66.05 -49.59 67.15 Favored 'General case' 0 N--CA 1.497 1.877 0 O-C-N 121.528 -0.733 . . . . 0.5 110.098 -179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 7.5 p -71.17 -32.88 49.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 O-C-N 121.673 -0.642 . . . . 0.65000000000000002 110.174 -179.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.29 -40.55 67.49 Favored 'General case' 0 N--CA 1.496 1.872 0 O-C-N 121.466 -0.772 . . . . 1.1100000000000001 110.0 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' MET . . . . . . . . . . . . . 32.5 mmm -80.23 -40.35 27.25 Favored 'General case' 0 N--CA 1.497 1.922 0 O-C-N 121.58 -0.7 . . . . 1.3500000000000001 109.777 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . . . . . . . . . . . 99.79 48.26 1.66 Allowed Glycine 0 N--CA 1.496 2.685 0 N-CA-C 109.535 -1.426 . . . . 0.81999999999999995 109.535 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.442 ' HB1' ' HB3' ' A' ' 23' ' ' ALA . . . -149.45 120.95 7.95 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.602 -0.94 . . . . 0.90000000000000002 109.724 -179.875 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 20.3 p -82.52 -58.87 2.73 Favored 'General case' 0 N--CA 1.499 1.976 0 O-C-N 121.586 -0.696 . . . . 2.02 109.546 -179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.69 63.77 8.24 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.536 -0.727 . . . . 2.5 109.307 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ALA . . . . . 0.442 ' HB3' ' HB1' ' A' ' 20' ' ' ALA . . . -179.85 -81.9 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.009 0 O-C-N 121.647 -0.658 . . . . 1.2 109.575 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . 0.436 ' HB2' ' HA ' ' A' ' 15' ' ' ALA . 9.7 m-20 . . . . . 0 N--CA 1.496 1.836 0 O-C-N 121.411 -0.806 . . . . 1.6000000000000001 109.612 179.894 . . . . . . . . 1 1 . 1 stop_ save_